

UNIVERSIDADE ESTADUAL DE MONTES CLAROS

Ludmilla Louise Cerqueira Maia Prates

Atividade de extratos de *Erythrina* spp. sobre o crescimento populacional e a formação de biofilme de *Streptococcus* do grupo *mutans*.

Montes Claros

2017

Ludmilla Louise Cerqueira Maia Prates

Atividade de extratos de *Erythrina* spp. sobre o crescimento populacional e a formação de biofilme de *Streptococcus* do grupo *mutans*.

Dissertação de Mestrado apresentada ao Programa de Pós-Graduação em Ciências em Saúde da Universidade Estadual de Montes Claros - Unimontes, como parte das exigências para a obtenção do título de Mestre em Ciências da Saúde.

Área de Concentração: Mecanismos e Aspectos Clínicos das Doenças

Orientador: Profa. Dra. Ana Cristina de Carvalho Botelho

Coorientador: Prof. Dr. Sérgio Avelino Mota Nobre

Montes Claros

2017

P912a

Prates, Ludmilla Louise Cerqueira Maia.

Atividade de extratos de *Erythrina* spp. sobre o crescimento populacional e a formação de biofilme de *Streptococcus* do grupo *mutans* [manuscrito] / Ludmilla Louise Cerqueira Maia Prates. – 2017.

48 f. : il.

Inclui Bibliografia.

Dissertação (mestrado) - Universidade Estadual de Montes Claros - Unimontes, Programa de Pós-Graduação em Ciências da Saúde/PPGCS, 2017.

Orientadora: Profa. Dra. Ana Cristina de Carvalho Botelho.

Coorientador: Prof. Dr. Sérgio Avelino Mota Nobre.

1. *Streptococcus* do grupo *mutans*. 2. Biofilme oral. 3. *Erythrina* spp. I. Botelho, Ana Cristina de Carvalho. II. Nobre, Sérgio Avelino Mota. III. Universidade Estadual de Montes Claros. IV. Título.

UNIVERSIDADE ESTADUAL DE MONTES CLAROS – UNIMONTES

Reitor: João dos Reis Canela

Vice-reitor: Antonio Alvimar Souza

Pró-reitor(a) de Pesquisa: Vírgilio Mesquita Gomes

Coordenadoria de Acompanhamento de Projetos: Karen Tôrres Corrêa Lafetá de Almeida

Coordenadoria de Iniciação Científica: Sônia Ribeiro Arrudas

Coordenadoria de Inovação Tecnológica: Dario Alves de Oliveira

Pró-reitor de Pós-graduação: Hercílio Martelli Júnior

Coordenadoria de Pós-graduação Lato-sensu: Felipe Froés Couto

Coordenadoria de Pós-graduação Stricto-sensu: Maria de Fátima Rocha Maia

PROGRAMA DE PÓS-GRADUAÇÃO EM CIÊNCIAS DA SAÚDE

Coordenadora: Marise Fagundes Silveira

Subcoordenador: Luiz Fernando Rezende



UNIVERSIDADE ESTADUAL DE MONTES CLAROS
PROGRAMA DE PÓS-GRADUAÇÃO EM CIÊNCIAS DA SAÚDE



MESTRANDO(A): LUDMILLA LOUISE CERQUEIRA MAIA PRATES

TÍTULO DO TRABALHO: "Atividade de extratos de Erythrina spp. sobre o crescimento populacional e a formação de biofilme de Streptococcus do grupo mutans".

ÁREA DE CONCENTRAÇÃO: Mecanismos e Aspectos Clínicos das Doenças.

LINHA DE PESQUISA: Clínica, Diagnóstico e Terapêutica das Doenças.

BANCA (TITULARES)

PROFª. DRª. ANA CRISTINA DE CARVALHO BOTELHO ORIENTADOR/PRESIDENTE

PROF. DR. HERCÍLIO MARTELLI JÚNIOR

PROFª. DRª. VERA LÚCIA ALVES

PROF. DR. SÉRGIO AVELINO MOTA NOBRE

ASSINATURAS

Ana Cristina C. Botelho
Hercilio Junior
Vera Lucia
Sergio Mota Nobre

BANCA (SUPLENTES)

PROF. DR. SÍLVIO FERNANDO GUIMARÃES DE CARVALHO

PROFª. DRª. LETÍCIA ANTUNES ATHAYDE

ASSINATURAS

Silvio Fernandes
Letícia Athayde

APROVADA

REPROVADA

Hospital Universitário Clemente Farias – HUCF

<http://www.unimontes.br> / ppgcs@unimontes.br

Telefone: (0xx38) 3224-8372 / Fax: (0xx38) 3224-8372

Av. Cula Mangabeira, 562, Santo Expedito, Montes Claros – MG, Brasil – Cep: 39401-001

Dedico a Deus, à minha filha Maria Luiza, aos meus pais, irmãos e amigos pelo apoio na realização deste trabalho.

AGRADECIMENTOS

Agradeço a Deus por me amparar nos momentos difíceis, me dar força interior para superar as dificuldades, mostrar os caminhos nas horas incertas e me suprir em todas as minhas necessidades.

Aos meus orientadores, professora Ana Cristina de Carvalho Botelho e professor Sérgio Avelino Mota Nobre, meu agradecimento mais que especial, pelo apoio, compreensão e exemplo de pessoa. Sua confiança e orientação foram fontes de meu bem estar e de êxito neste trabalho. Muito Obrigada.

A minha família que sempre me apoiou com palavras de conforto e incentivo.

Aos meus amigos do Laboratório de Epidemiologia e Biocontrole de Micro-organismo – LEBM em especial a Ronize, Geisy, Lucas, Thais e Letícia que colaboraram para a realização deste trabalho.

Ao Programa de Pós-Graduação em Ciências da Saúde – PPGCS, por permitir o desenvolvimento deste trabalho.

RESUMO

Biofilmes representam importante estratégia de sobrevivência de microrganismos em ambientes úmidos, como a cavidade bucal humana, resultando em processos infecciosos. Dentre as doenças bucais a cárie dentária se apresenta como uma das mais prevalentes doenças humanas, principalmente na infância. O processo cariioso se configura como uma doença de caráter crônico e multifatorial que esta estreitamente relacionada com a presença de *Streptococcus* do grupo *mutans*, principalmente *S. mutans*. Aquisição de *S. mutans*, juntamente com a ingestão elevada de açúcar, estabelece um ambiente favorável para o desenvolvimento da cárie. Este microrganismo está sempre presente no biofilme dental potencialmente cariogênico. Além disso, há uma forte evidência que a produção de glucanos é essencial para a expressão da virulência de *Streptococcus* do grupo *mutans*, contribuindo para a aderência efetiva da bactéria à superfície dental, pela exposição à sacarose. Além das reconhecidas medidas de prevenção da cárie dental, como os procedimentos mecânicos de remoção do biofilme cariogênico, a adequação da dieta e o uso do flúor, tem-se investigado novas estratégias. Como terapia alternativa tem se buscado novos agentes antimicrobianos de origem natural, em especial de plantas. Em geral, estes agentes antimicrobianos fitoterápicos exibem diversas estruturas que reduzem o potencial de surgimento de populações microbianas resistentes. O objetivo deste trabalho foi avaliar a atividade de extratos da casca de *Erythrina* spp. sobre o crescimento populacional e a formação de biofilme de *Streptococcus* do grupo *mutans*. Foi utilizada coleção de bactérias deste grupo taxonômico, originária de biofilmes posicionados, distintamente, nas faces palatina e vestibular da cavidade bucal de crianças em fase pré-escolar. Ensaio de produção de biofilme foram conduzidos em vidro e hidroxiapatita (HPA), nos quais foram selecionados três isolados com níveis distintos de virulência. Para os ensaios de inibição diante dos extratos de *Erythrina* spp, foram incluídas as cepas de ampla referência ATCC 25175 (*S. mutans*) e ATCC 27392 (*S. sobrinus*) conduzidos em microplacas. A eficiência da inibição das bactérias variou com o modo de obtenção do extrato e com a virulência dos isolados. Os resultados foram promissores para as concentrações acima de 750 µg/mL, com inibições significativas do crescimento bacteriano e desestruturação dos biofilmes dos isolados em HPA.

Palavras-Chave: *Streptococcus* do grupo *mutans*, biofilme oral, *Erythrina* spp.

ABSTRACT

Biofilms represent an important survival strategy for microorganisms in humid environments, such as the human oral cavity, resulting in infectious processes. Among oral diseases, dental caries presents as one of the most prevalent human diseases, especially in childhood. The carious process is characterized as a chronic and multifactorial disease which is related to the presence of *Streptococcus mutans* group, especially *S. mutans*. Acquisition of *S. mutans*, along with high intake of sugar, establishes a favorable environment for the development of caries. This microorganism is always present in the potentially cariogenic dental biofilm. In addition, there is strong evidence that glucan production is essential for expression of the *Streptococcus mutans* group virulence, contributing to the effective adherence of the bacterial to the dental surface, through exposure to sucrose. In addition to the recognized measures of prevention of dental caries, such as the mechanical procedures of cariogenic biofilm removal, the adequacy of diet, and the use of fluorine, new strategies are investigated. As alternative therapy are sought new antimicrobial agents of natural origin, especially of plants. In general, these phytotherapeutic antimicrobial agents exhibit diverse structures that reduce the potential for emergence of resistant microbial populations. The objective of this work was to evaluate the activity of extracts of *Erythrina* spp bark on population growth and biofilm formation of *Streptococcus mutans* group. A collection of bacteria from this taxonomic group, derived from biofilms positioned, was used distinctly on the palatal and vestibular surfaces of the oral cavity of pre-school age children. Biofilm production assays were conducted on glass and hydroxyapatite (HPA), in which three isolates with different levels of virulence were selected. In the inhibition assay with *Erythrina* spp. extracts, reference strains ATCC 25175 (*S. mutans*) and ATCC 27392 (*S. sobrinus*) were included, conducted on microplates. The efficiency of inhibition of the bacteria varied with the mode of extraction of the extract and with the virulence of the isolates. The results were promising for concentrations above $750\mu\text{g.mL}^{-1}$, with significant inhibitions of bacterial growth and disruption of the biofilms of HPA isolates.

Key words: *Streptococcus mutans* group, oral biofilm, *Erythrina* spp.

SUMÁRIO

1 INTRODUÇÃO.....	9
1.1 Cárie	9
1.2 <i>Streptococcus</i> do grupo <i>mutans</i>	10
1.3 Biofilme	11
1.3.1 Biofilme oral.....	13
1.4 Produtos naturais como inibidores de biofilme	14
1.4.1 <i>Erythrina</i> spp.	15
2 OBJETIVOS.....	16
2.1 Objetivo Geral	16
2.2 Objetivos Específicos	16
3 PRODUTO CIENTÍFICO	17
3.1 Artigo 1: Activity of extracts of <i>Erythrina</i> spp. on population growth and biofilm formation of <i>Streptococcus mutans</i> group.....	18
4 CONCLUSÕES	37
REFERÊNCIAS	38
ANEXO	44

1 INTRODUÇÃO

Cárie

A cárie dentária é uma doença multifatorial de dieta dependente, caracterizada pela desmineralização localizada do tecido dentário (esmalte, dentina e cemento) (1). Apesar dos avanços na redução de incidência, continua sendo um processo com elevado índice de prevalência em seres humanos (2,3). O processo de formação de cárie dentária tem sido intensivamente estudado (4,5), vários modelos foram propostos para tentar explicar esse processo de formação. O primeiro é essencialmente ecológico, no qual a carie é caracterizada pela interação de três fatores determinantes: hospedeiro, dieta e microbiota (6). O segundo modelo proposto acrescentou o fator tempo nessa interação, no entanto ambos os modelos não foram capazes de explicar de forma efetiva a ocorrência da doença na população humana (7).

A doença cárie é muito mais complexa e com um caráter comportamental, dessa maneira podendo ser influenciada por fatores modificadores ou extrínsecos. Com relação à suscetibilidade à cárie, o indivíduo pode apresentar fatores extrínsecos relacionados à estrutura sociocultural (classe social, renda, conhecimento, atitude e escolaridade) e fatores intrínsecos como fluxo, composição e capacidade tampão da saliva, aspectos hereditários e imunológicos difíceis de serem controlados. Sendo o fator suscetibilidade de grande importância para as estratégias de prevenção (8-10).

As lesões cariosas podem ocorrer sobre todas as superfícies do dente onde o biofilme se possa formar, sendo mais comumente encontrada em fissuras, sulcos e áreas proximais (11). Apesar de ser uma doença de maior incidência na infância, também acomete indivíduos com idade avançada, nos quais é possível observar cárie na superfície radicular por exposição da raiz do dente devido à regressão gengival (12). Clinicamente, a cárie apresenta-se como uma cavidade ou fissura na superfície do dente, sendo inicialmente assintomática. Com a progressão da infecção, os pacientes podem apresentar sensibilidade dentária com dor leve ou grave, dependendo da severidade da lesão (13). O controle e até mesmo a reversão da cárie é possível caso seja diagnosticada em estágio inicial, mancha branca no esmalte do dente, sem presença de cavidades ou fissuras. No caso de cavidades dentárias, há a necessidade de

tratamento curativo e preventivo, a fim de impedir a evolução da doença que pode causar grande destruição dos dentes, até mesmo a perda, resultando em complicações locais, sistêmicas, psicológicas e sociais (14).

O processo cariogênico ocorre quando bactérias acidogênicas (capazes de produzirem ácidos a partir da fermentação de carboidratos da dieta) e acidúricas (sobrevivem em meio ácido) que interagem com outros microrganismos no biofilme sobre a superfície do dente ocasionam a erosão ou à desmineralização do tecido dentário mais externo através de ácidos, em especial o lático (15-17).

Os principais grupos de bactérias que produzem ácido lático são *Streptococcus* do grupo *mutans* e *Lactobacillus*. Esses grupos de bactérias, atuando em conjunto ou isoladamente, são os principais causadores da cárie dentária (18,19). Os microrganismos com mais destaque no processo cariogênico são os *Streptococcus* do grupo *mutans*, totalizando são cerca de 60% dos microrganismos que compõem o biofilme dentário (20). No entanto também são encontrados *Actinomyces viscosus* que esta relacionado com início da lesão cariosa (21).

Streptococcus do grupo *mutans*

Streptococcus do grupo *mutans* (SGM) foram isolados no início do século XX, e descritos como “mutantes” por sua morfologia celular ser mais achatada do que outros estreptococos (22). Relacionam-se as espécies: *S. mutans*, *S. sobrinus*, *S. salivarius*, *S. mitis*, *S. gordonii*, *S. sanguinis*, *S. rattus*, *S. downei*, *S. macacae*, *S. feru* (23). Sendo as espécies *S. mutans* e *S. sobrinus* mais frequentes em humano, com maior prevalência da espécie *S. mutans* (5). Os *Streptococcus* do grupo *mutans* são classificados dentro de 8 sorotipos (*a-h*), sendo os encontrados em humanos *c*, *e* e *f* (*S. mutans*) e *d* e *g* (*S. sobrinus*) (9).

SGM são bactérias gram positivas presentes no biofilme dental potencialmente cariogênico, sendo considerados como um dos principais microrganismos associados com início e patogenia da cárie humana. (23-25). O *S. mutans* usualmente coloniza a superfície dentária, mas também pode ser encontrado na língua, saliva e membranas da mucosas. Embora a maioria dos casos de colonização de *S. mutans* não apresentarem consequências graves, esses

microrganismos podem adaptar ao ambiente, resistir à defesa imunológica, colonizar os tecidos cardíacos e causar endocardite infecciosa. Também sendo responsável por algumas inflamações oculares de neonatos (26).

A endocardite infecciosa é uma doença sistêmica grave e muitas vezes fatal. Foi observado a partir de 2007 um aumento significativo da incidência de endocardite infecciosa causada por estreptococos (27). Essas bactérias são capazes de sintetizar polissacarídeos extracelulares insolúveis, por meio de enzimas glicosiltransferases (*GTFs*) o que promove o acúmulo e permanência dos microrganismos no dente (28,29). A capacidade de sintetizar glucanos, na presença de sacarose, representa importante fator de virulência associado SGM (5,30).

A enzima glicosiltransferase (*GTF*) secretada pelo *Streptococcus* do grupo *mutans* hidrolisa a sacarose em glicose e frutose e polimeriza as moléculas de glicose liberadas, sintetizando polissacarídeos, glucanos, que irão constituir a matriz extracelular da placa bacteriana. Diversos tipos de glucanos são produzidos, os quais variam na solubilidade em água, onde *GTF B*: responsável pela produção de glucanos insolúveis em água, *GTF C*: pela produção de glucanos solúveis e insolúveis e *GTF D*: pela produção de glucanos solúveis. Os glucanos insolúveis em água são aqueles onde prevalecem às ligações do tipo α -(1-3) entre as moléculas de glicose, e são os mais importantes na formação de uma matriz extracelular insolúvel, essencial para o acúmulo de *S.* do grupo *mutans* no biofilme dentário dental (31-36).

Os glucanos promovem o acúmulo de SGM na superfície dental e contribuem para o volume, cariogenicidade e integridade estrutural do biofilme dental e, além de ser um essencial fator de virulência dos SGM relacionado a patogênese da cárie dental (35), são reserva de energia para bactérias, reguladores da permeabilidade da placa dental controlando a acidez nos dentes (37).

Biofilme

A maior parte da atividade bacteriana na natureza ocorre, não com as células individualizadas crescendo de maneira planctônica (livres, em suspensão), mas com as bactérias organizadas

em comunidades de diferentes graus de complexidade, associadas a superfícies diversas, geralmente compondo um biofilme. Esses biofilmes são constituídos por células aderentes a uma superfície inerte (abiótica) ou viva (biótica), embebidas numa matriz de exopolissacarídeo. A associação dos organismos em biofilmes constitui uma forma de proteção ao seu desenvolvimento, fomentando relações simbióticas e permitindo a sobrevivência em ambientes hostis (38-40).

Os biofilmes na natureza são dos mais diversos ao nível filogenético, sendo geralmente constituídos por vários tipos de microrganismos (bactérias, arqueas, fungos filamentosos, leveduras e alga unicelulares como diatomáceas), podendo os produtos do metabolismo de uma espécie auxiliar o crescimento das demais e a adesão de uma dada espécie fornecer substâncias que promovem a ligação de outras. Inversamente, a competição pelos nutrientes e a acumulação de metabólitos tóxicos produzidos pelas espécies colonizadoras poderão limitar a diversidade de espécies num biofilme (41-42).

Dos microrganismos frequentemente encontrados num biofilme, as bactérias são o grupo predominante (43). As elevadas taxas de reprodução, grande capacidade de adaptação e de produção de substâncias e estruturas extracelulares, são as principais características que as fazem organismos com grandes capacidades de produção de biofilme (29).

Os biofilmes são encontrados em diversas áreas podendo ter função benéfica ou prejudicial na atividade humana. No contexto industrial, os biofilmes são utilizados em diversos processos de base tecnológica como forma de resolver alguns problemas causados pela atividade humana, como exemplo no tratamento de resíduos e de contaminações do meio ambiente (44). No entanto, os biofilmes são também responsáveis por elevadas perdas econômicas quando estão associados a problema de corrosão, de perda de carga de fluidos em tubagens ou de contaminações em produtos alimentares (45).

No contexto clínico, os biofilmes têm tipicamente um papel prejudicial. A sua ação é fundamental quer na progressão de infecções associadas à colonização de dispositivos médicos inseridos no corpo humano, quer associadas à colonização direta de tecidos, como é o caso da fibrose cística. Entretanto, são conhecidos alguns exemplos de biofilmes com ação protetora na saúde. Por exemplo, no trato gastrointestinal, biofilmes mistos aderidos a células epiteliais podem formar uma barreira que impede o acesso de microrganismos patogênicos

(46,47). Da mesma forma, a formação de biofilmes nos dentes ou na vagina por microrganismos comensais impedem que microrganismos patogênicos possam formar eles biofilmes. Quando os biofilmes comensais são perturbados nestas situações, surgem problemas como cárie ou vaginoses bacterianas (42).

Biofilme oral

A cavidade oral é um ambiente único caracterizado pela presença constante de água na saliva, por uma grande variação da entrada de carbono e azoto, temperatura entre 35 a 36°C, pH entre 6,75 e 7,25, e ainda pela presença de superfícies distintas, como os dentes, os sulcos gengivais, a língua, o palato duro ou mole (48).

A regulação da formação de biofilme oral apresenta vários fatores, estando dependente da capacidade de os microrganismos sobreviverem a condições adversas, da sua capacidade de obter nutrientes a partir do ambiente, de crescer rapidamente como os microrganismos vizinhos, e da sua capacidade, enquanto comunidade microbiana, de se adaptar aos fatores ambientais (37,48).

A formação do biofilme ocorre através de um processo ordenado e dinâmico onde há necessidade da fixação e proliferação de bactérias sobre as superfícies dos dentes (49), sendo formado por uma película incolor aderente e não mineralizada, composta por diversos microrganismos, sustentada por uma matriz de proteínas salivares, polissacarídeos, células, leucócitos e restos alimentares. Sendo de difícil remoção (50-53).

O biofilme oral apresenta as seguintes etapas de formação: adesão reversível e irreversível, maturação e dispersão. Na adesão bacteriana, as bactérias planctônicas, que são transportadas passivamente na saliva e no fluido gengival, sem contato direto com a superfície do dente podem estabelecer interações físico-químicas fracas entre microrganismos e a película adquirida no dente, o que facilita a adesão não específica e reversível das bactérias. Seguidamente, pode ocorrer a adesão específica e irreversível das bactérias à película adquirida. Ocorre a formação de microcolônias, fenômenos de co-adesão, onde as bactérias se ligam a células microbianas distintas que já se encontram aderidas à película adquirida do

dente. Na maturação as células além de proliferarem, com conseqüente aumento de biomassa, sintetizam e degradam polímeros. E a dispersão, no qual as células do biofilme se desprendem para criar um novo foco de infecção (54,55).

A disrupção de um ou mais fatores ambientais pode induzir alterações na homeostasia da comunidade do biofilme oral, induzindo um estado de doença (33). O controle mais comumente utilizado é o método mecânico através principalmente da escovação, porém este método possui algumas limitações e por este motivo associa-se a métodos químicos para a desestruturação deste biofilme cariogênico (56). Apesar da associação com método químico ser muitas vezes eficaz o desenvolvimento de resistência pelos microrganismos a antimicrobianos e compostos sintéticos usuais tem levado pesquisadores de diversas áreas a buscar alternativas em produtos naturais empregados na medicina tradicional para combater as mais diversas variedades de patologias bucais (57-59).

Produtos naturais como inibidores do biofilme

Em decorrência da incidência de doenças orais, do aumento da resistência de bactérias aos antibióticos e dos efeitos adversos de alguns agentes antibacterianos usados na odontologia, existe a necessidade de novas alternativas de prevenção e tratamento que sejam seguras, efetivas e econômicas (60).

As plantas são uma fonte importante de produtos naturais biologicamente ativos, muitos dos quais se constituem em modelo para a síntese de um grande número de fármacos. Pesquisadores da área de produtos naturais mostram-se impressionados pelo fato desses produtos encontrados na natureza revelarem uma gama quase que inesgotável de diversidade em termos de estrutura e de propriedades físico-químicas e biológicas (60-62). Apesar do aumento de estudos nessa área, os dados disponíveis revelam que apenas 15 a 17% das plantas foram estudadas quanto ao seu potencial medicinal (59).

Diversos trabalhos relatam o uso bem sucedido de produtos farmacêuticos à base de extrato vegetal. A ausência de efeitos colaterais associada a baixo custo de produção é considerado de

fundamental importância para o seu desenvolvimento. Assim extratos ou substâncias isoladas de plantas medicinais ou de outros produtos encontrados na natureza podem ser pesquisados como alternativas terapêuticas para o controle do biofilme dental cariogênico (63,64).

Erythrina spp.

O gênero *Erythrina* pertence à família Fabaceae contém cerca de 130 espécies com distribuição em regiões tropicais e subtropicais dos hemisférios norte e sul. O nome genérico *Erythrina* vem do grego “erythros” que significa vermelho, em decorrência da cor das flores das espécies do gênero (65).

Espécies de *Erythrina* são comumente utilizadas para vários tipos de doenças humanas na medicina popular (66). Estudos realizados anteriormente nesse gênero mostram uma rica fonte de alcalóides bioativos e flavonóides, em especial, isoflavonas e flavononas (67).

No Brasil são encontradas cerca de onze espécies deste gênero. São elas: *E. verna* (*E. mulungu*), *E. falcata*, *E. dominguezii*, *E. amazonica*, *E. velutina*, *E. crista-galli*, *E. fucas*, *E. poeppigiana*, *E. speciosa*, *E. similis*, *E. ulei* (68). As plantas deste gênero possuem diferentes ações farmacológicas como: *Erythrina verna* antidepressiva, sedativa, ansiolítica, antibacteriana e tônico hepático (69); *Erythrina caffra* é usada para tratar dor de ouvido, entorses, feridas, tuberculose, infecções respiratórias, abscessos, artrite e dor de dente (66,67); *Erythrina sigmoidea* como antídoto (picadas venenosas, picadas, etc.), diurético, febril e tratamento de artrite, reumatismo, problemas pulmonares, problemas de estômago, doenças infecciosas e doenças renais (70); *Erythrina velutina* como sedativo, calmante, sudorífica, emoliente, anestésico (71,72).

2 OBJETIVOS

Objetivo Geral

Avaliar a atividade de extratos de *Erythrina* spp. sobre o crescimento populacional e a formação de biofilme de *Streptococcus* do grupo *mutans*.

Objetivos Específicos

- Estimar a concentração inibitória mínima (CIM) de extratos da casca de *Erythrina* spp. sobre *Streptococcus* do grupo *mutans*.
- Estimar a concentração bactericida mínima (CBM) de extratos da casca de *Erythrina* spp. sobre *Streptococcus* do grupo *mutans*.
- Mensurar o efeito *in vitro* dos extratos em diferentes concentrações sobre a produção biofilme por *Streptococcus* do grupo *mutans*.
- Avaliar a presença de compostos secundários dos extratos de *Erythrina* spp.

3 PRODUTO CIENTÍFICO

Produto 1: Activity of extracts of *Erythrina* spp on population growth and biofilm formation of *Streptococcus mutans* group, formatado segundo as normas para publicação do periódico Brazilian Journal of Microbiology.

1 **Activity of extracts of *Erythrina* spp on population growth and biofilm formation of**
 2 ***Streptococcus mutans* group.**

3 **Phytotherapeutic control of dental biofilm**

4 **Authors:** Ludmilla Louise Cerqueira Maia Prates^{1*}, Ronize Viviane Jorge de Faria^{1*}, Gezilene
 5 Fernandes de Souza¹, Verônica Oliveira Dias², Hercílio Martelli Júnior², Ana Cristina de Carvalho
 6 Botelho³, Sérgio Avelino Mota Nobre¹

7 ¹Epidemiology and Biocontrol of Microorganism Laboratory, Universidade Estadual de Montes
 8 Claros, Brasil.

9 ²Universidade Estadual de Montes Claros.

10 ³Faculdade Integrada Pitágoras.

11 *Graduate Program in Health Sciences – Universidade Estadual de Montes Claros.

12

13 **ABSTRACT**

14 Biofilms represent important strategy for the survival of microorganisms in humid environments, as
 15 the human oral cavity, resulting in infectious processes. Among oral diseases, dental caries is one of
 16 the most prevalent, especially in childhood, being of a chronic and multifactorial character that is
 17 associated with the presence of *Streptococcus mutans* group. This bacteria is always present in the
 18 potentially cariogenic dental biofilm. In addition to the recognized measures of prevention of this
 19 disease, such as mechanical procedures to remove biofilms, dietary adequacy and use of fluoride, new
 20 strategies are investigated. As alternative therapy are sought new antimicrobial agents of natural
 21 origin, especially of plants. In general, these phytotherapeutic antimicrobial agents exhibit diverse
 22 structures that reduce the potential for emergence of resistant microbial populations. The objective of
 23 this work was to evaluate the activity of extracts of *Erythrina* spp bark on population growth and
 24 biofilm formation of *Streptococcus mutans* group. A collection of bacteria from this taxonomic group,
 25 derived from biofilms positioned, was used distinctly on the palatal and vestibular surfaces of the oral
 26 cavity of pre-school age children. Biofilm production assays were conducted on glass and
 27 hydroxyapatite (HPA), in which three isolates with different levels of virulence were selected. In the
 28 inhibition assay with *Erythrina* spp. extracts, reference strains ATCC 25175 (*S. mutans*) and ATCC
 29 27392 (*S. sobrinus*) were included, conducted on microplates. The efficiency of inhibition of the
 30 bacteria varied with the mode of extraction of the extract and with the virulence of the isolates. The
 31 results were promising for concentrations above 750µg.mL⁻¹, with significant inhibitions of bacterial
 32 growth and disruption of the biofilms of HPA isolates.

33 **Key words:** *Streptococcus mutans* group, oral biofilm, *Erythrina* spp.

34 Introduction

35 Dental carie although presenting a significant decline in some populations, continues to be an
36 important public health problem¹. It is a multifactorial, transmissible and diet dependent disease
37 caused by specific types of acid producing bacteria that cause demineralization and destruction of the
38 teeth being induced by the decrease of the pH of the dental plaque.²⁻⁵

39 The microbial nature of dental caries involves taxonomically organized bacteria such as *Streptococcus*
40 *mutans* group (SMG).^{6,7} It is a polyphyletic group, with expressive genetic and physiological
41 variability, being distinguished by serotyping.

42 The following species are related: *S. mutans*, *S. sobrinus*, *S. salivarius*, *S. mitis*, *S. gordonii*, *S.*
43 *sanguinis*, *S. rattus*, *S. downei*, *S. macacae*, *S. ferus*.⁸ The species *S. mutans* and *S. sobrinus* are
44 exclusive to humans, with a higher prevalence of the *S. mutans* species.⁹ The *Streptococcus mutans*
45 group are classified into 8 serotypes (*a-h*), being found in humans *c*, *e* and *f* (*S. mutans*) and *d* and *g*
46 (*S. sobrinus*)¹⁰. In addition to dental caries *Streptococcus mutans* is also important cause of infective
47 endocarditis. In a recent study, it was observed that from 2007 the incidence of infective endocarditis
48 caused by streptococci increased significantly, being this species isolated from 8-10% of the patients
49 with endocardial disease and 14.2% of the patients with cardiovascular diseases caused by
50 streptococci¹¹.

51 These bacteria have spherical shapes and positive response for Gram staining (GPC), colonizing the
52 surface of the teeth and participating in the formation of oral biofilm¹². This biofilm consists of a
53 complex and structured community of microorganisms adhered to a biotic or abiotic surface immersed
54 in a matrix of extracellular polymers under the continuous action of a flow.^{12,13} The formation of the
55 biofilm occurs through an orderly and dynamic process where there is a need for the fixing and
56 proliferation of bacteria on the surfaces of the teeth (reversible and irreversible bacterial adhesion),
57 maturation and dispersion¹⁴. The most commonly used control is the mechanical method principally
58 through brushing, but this method has some limitations and for this reason it is associated to chemical
59 methods for restructuring of this cariogenic biofilm.^{15,16}

60 Although the association with chemical method is often effective the development of resistance by the
61 microorganisms the usual antimicrobial and synthetic compounds has led researchers from several
62 areas to seek alternatives in natural products used in traditional medicine to combat the most diverse
63 varieties of oral pathologies.¹⁷⁻²⁰


64 Plants are important sources of natural therapeutic products, many of which are a model for the
65 synthesis of a large number of drugs. Studies report that plant extracts and phytochemicals compound
66 have been used more frequently for medicinal aim.²¹⁻²⁶ The World Health Organization estimates that
67 65-80% of the population in developing countries depend on medicinal plants as the only form of

68 basic health care.²⁸⁻²⁹ It is estimated that Latin American countries has part of the world's biodiversity,
 69 with Brazil accounting for approximately 22% of all plant and microbial species on the planet.²⁹
 70 Essential oils, flavonoids, alkaloids, tannins, quinones among other substances are isolated from
 71 plants, are described in the literature because they present antibacterial activity.³⁰⁻³²

72 The genus *Erythrina* belongs to the *Fabaceae* family distributed in tropical and subtropical regions of
 73 the northern and southern hemispheres. The generic name *Erythrina* comes from the greek "erythros"
 74 which means red, because of the color of the flowers of the species of the genus. In Brazil, about 11
 75 species of this genus are found, being *E. verna* (*E. mulungu*), *E. falcata*, *E. dominguezii*, *E.*
 76 *amazonica*, *E. velutina*, *E. crista-galli*, *E. fucas*, *E. poeppigiana*, *E. speciosa*, *E. similis*, *E. ulei*.³³
 77 *Erythrina verna* antidepressant, sedative, anxiolytic, antibacterial and hepatic tonic³⁴; *Erythrina caffra*
 78 is used to treat earache, sprains, wounds, tuberculosis, respiratory infections, abscesses, arthritis and
 79 toothache³⁵⁻³⁶; *Erythrina sigmoidea* as antidote (poisonous stings, stings, etc.), diuretic, febrile and
 80 treatment of arthritis, rheumatism, lung problems, stomach problems, infectious diseases and renal
 81 diseases³⁷; *Erythrina velutina* as sedative, soothing, sudorific, emollient, anesthetic^{38,39}.

82 The objective of this work was to investigate the inhibitory activity of extracts of *Erythrina* spp.,
 83 considering isolates of *Streptococcus mutans* group, obtained from the oral cavity of pre-school
 84 children, selected and categorized as to adhesion capacity and biofilm formation.

85



86

87 **Fig. 1 – Organogram with steps and procedures used during the evaluation process of extracts of**
 88 ***Erythrina* spp. on population growth and biofilm formation of *Streptococcus mutans* group.**

89

90 Materials and methods*91 Origin of isolates*

92 A collection of 28 isolates belonging to the Laboratory of Epidemiology and Biocontrol of
93 Microorganism of the State University of Montes Claros was used. The isolates originated from dental
94 biofilms of pre-school children, positioned distinctly in the oral cavity: (I) palatine face and (ii)
95 vestibular face, being coded by the letters P and V respectively. Strains of the American Type Culture
96 Collection, ATCC 25175 (*S. mutans*), and ATCC 27392 (*S. sobrinus*) were also used.

97 Selection of isolates of Streptococcus mutans group

98 The process of selection of isolates *Streptococcus mutans* group (SMG) was done from two adhesion
99 assays, being the first on glass surface and second on hydroxyapatite crystals (HPA). The glass
100 surface assay was adapted from Kim et al. (2011)⁴⁰ using Broth Heart Infusion (BHI-Oxoid England)
101 added with 1% sucrose (BHIS). The inoculum was adjusted on the McFarland 0.5 scale and the cell
102 concentration was approximately 10^8 cfu.mL⁻¹. Aliquots of 10mL of the broth, previously inoculated,
103 were distributed in glass tubes, and incubated in an inclined position (30°) for 24h at 37°C in
104 anaerobiosis. To evaluate the bacterial cells adhered to the wall of the tube, the supernatant was
105 initially discarded and then the surfaces of the biofilm were washed with SDW (sterile distilled water).
106 This procedure was repeated twice for removal of cells that did not adhere efficiently. Five milliliter of
107 potassium phosphate buffer (0.05M, pH 6.8) containing 0.02% sodium azide was added and sequence
108 was performed: vortex shaking (1-Ika); detachment of the adhered bacterial cells with the aid of glass
109 stick and more vortex shaking. Subsequently, serial decimal dilution (10^{-1} to 10^{-6}) of the suspension of
110 suspension buffer-biofilm cells and 100µL aliquots were spread, in triplicate on BHI agar. The plates
111 were incubated for 24h at 37°C, in anaerobiosis, followed by direct counting of the colonies and the
112 results recorded (ufc.mL⁻¹). The adhesion assay on hydroxyapatite (HPA) crystals was adapted from
113 the methodology of Fukushima et al. (1992).⁴¹ Three hundred micrograms of HPA crystals (diameter,
114 80µm, Bio-Rad, Hercules, CA, USA) were immersed in human saliva previously sterilized by
115 centrifugation (300rpm for 5 minutes) and clarification. The system was left standing for 1 hour at
116 room temperature. Saliva-coated HPA crystals were washed three times with potassium phosphate
117 buffer and immersed in 2mL of bacterial suspension (10^8 cfu.mL⁻¹). After incubation, accompanied by
118 slight shaking of the HPA crystals with the bacteria for 24h at 37°C, the crystals were washed with
119 SDW and potassium phosphate buffer added. The cells of the *Streptococcus mutans* group adhered to
120 the HPA were detached using the vortex apparatus, diluted and spread on plates containing Agar Mitis
121 Salivarius (AMS - HIMEDA), the latter process performed in triplicate. After incubation for 24h at
122 37°C in anaerobiosis, the colony forming units (ufc.mL⁻¹) were counted. Three isolates of SMG were


123 selected, being one of each class of virulence: high, medium and low. The quantitative definition of
 124 these levels was based on analyzes of the values obtained in the above mentioned assays.

125 *Vegetable species and extraction of extracts*

126 The species *Erythrina* spp. was collected in the locality called Vale do Arapuim, city of Varzelândia
 127 with coordinates 15.76107°S and 043.85611°W. The botanical material was identified by a specialist
 128 and the voucher was deposited in the herbarium of the State University of Montes Claros voucher
 129 number 5802. The collected plant material (bark) went through the process of asepsis, then dried in a
 130 forced-circulation oven (FANEM, 502) at 50°C, crushed and pulverized in industrial blender
 131 (VITALEX) and knife mill (TECNAL) with subsequent sieving.⁴¹ To prepare the cold extracts were
 132 weighed 50g of the powdered vegetable material and transferred to an amber bottle, where 500 ml of
 133 the solvent (hexane, dichloromethane, ethyl acetate and butanol (VETEC)) were added. The vials were
 134 stored for five days, with daily agitation and homogenization. After this time the extracts were filtered
 135 to retain the larger fragments. Thereafter vacuum filtration of the liquid extracts was carried out.
 136 Soxhlet extraction was also extracted by dragging, where 50g of the plant material was used for
 137 500mL of the solvent (hexane, dichloromethane, ethyl acetate and butanol). The other extraction
 138 process was conducted in Soxhlet, using the same proportions mass:solvent, however without
 139 fractionation. The extracts were dried in a forced circulation oven at 50°C.

140 *Quality control and interference of the diluent in the extract*

141 The minimum inhibitory concentration (MIC) of dimethylsulfoxide (DMSO), to be used as dilution of
 142 the dry extracts (DE) was determined in a pilot assay. Five SMG isolates were used (three selected in
 143 the adherence assays and two of wide reference: ATCC 27392 and ATCC 25175). The concentration
 144 used for the diluent was 6.25% (Fig. 2).



145

146 **Fig. 2 - Inhibition curves of the *Streptococcus mutans* group, as a function of DMSO**
 147 **concentrations, for use as diluent of plant extracts of *Erythrina* spp.**

148 *Phytochemical analysis of dry extracts*

149 The DE were investigated for the presence of secondary compounds. The classes of substances
 150 considered were: alkaloids, tannins, flavonoids, saponin, steroids and triterpenes. The analyzes were
 151 performed according to Matos.⁴²

152 *Minimum Inhibitory Concentration (MIC) of the extracts on the growth of SMG.*

153 The minimum inhibitory concentration (MIC) of each plant extract was evaluated in microdilutions,
 154 according to CLSI (Clinical and Laboratory Standards Institute), using 96-well sterile acrylic plates⁴³.
 155 The volumes for each well were: 80µL BHI, 100µL of the extract specific concentration and 20µL of
 156 the inoculum of the SMG isolate. The evaluated concentrations of the extracts were: 3000, 1500, 750,
 157 375, 187.5 and 93.75µg.mL⁻¹. Three previously selected SMG isolates were used, in addition to two
 158 broad reference strains (ATCC 27392 and ATCC 25175). Chlorhexidine (CLX - 0.12% v/v) was used
 159 as the reference chemotherapeutic treatment. A control treatment of culture broth sterility (CBS),
 160 extract diluent (CDS), of each extract (CES) and a control treatment of the number of bacteria
 161 inoculated for each SMG used (CI). Each treatment was performed in triplicate, being each well a
 162 repeat. The microplate was incubated at 37°C for 24h in anaerobiosis. After the incubation period, 20
 163 µL of 0.01% aqueous resazurin solution (RES) was added to each well. The RES was pre-sterilized by
 164 filtration on a 0.22µm hydrophilic filter membrane (Millex, Millipore ®). The microplates were
 165 incubated for an additional 120 minutes and then the visual evaluation was performed, where the blue
 166 color was interpreted as absence of microbial growth and red to pink color, as the presence of
 167 metabolically active SMG. MIC was defined as the lowest concentration of the extract whose color
 168 remained blue. Aliquots of 10µL were removed from each well in blue and the first in a pink color and
 169 scattered on BHI Agar surface for subsequent direct counting of the colonies. The minimum
 170 bactericidal concentration (MBC) was defined as the lowest concentration of the extract capable of
 171 causing 99.9% death of SMG cells, in relation to the control of the number of inoculated bacteria for
 172 each SMG used (CI). The plates were incubated at 37°C for 24h in anaerobiosis, and subsequently the
 173 number of colonies was measured in each replicate. Absence of bacterial growth after 24h of
 174 incubation determined MBC. Calculations were done according to ISO 7218.⁴⁴

Where:

$$N = \frac{\sum c}{V \times 1,1 \times d}$$

N= Number of microorganisms present in the test sample
 as a weighted mean from two successive dilutions;

$\sum c$ = Sum of the colonies counted in the two plates
 retained from two successive dilutions, at least one of

which contains a minimum of 10 colonies;

V = Volume of inoculum placed in each plate, in millilitres;

d = Dilution corresponding to the first dilution retained.

175

176 *Effect of the extracts in biofilm formation on hydroxyapatite crystals*

177 The procedures applied in the stage of colonization of the crystals by the selected SMG, followed the
 178 methodology described previously, in the HPA adhesion assay. The procedures for the application of
 179 extracts and measurement of biofilms are discussed below: (i) application of the extracts - the crystals
 180 were lightly washed twice with SDW and subsequently immersed in the extracts, at concentrations of
 181 $1500\mu\text{g}\cdot\text{mL}^{-1}$ to $350\mu\text{g}\cdot\text{mL}^{-1}$. The system was incubated again under conditions already described; (ii)
 182 biofilm measurement - The HPA crystals were washed lightly with SDW, followed by the addition of
 183 potassium phosphate buffer. The apparatus was vortexed, followed by serial decimal dilution with
 184 subsequent withdrawal of aliquots for direct counting of the disintegrated cells of the biofilm on MSA.
 185 The same procedure described above was performed in another assay to determine the preventive
 186 effect, where the HPA crystals were pretreated with the extracts and then inoculated with SMG. To
 187 better understand the effects, the inhibition index of each MS was calculated to each SMG isolate,
 188 considering the control treatment (Absence of inhibitory factor).

Where:

$Inb_{n-z}(\%)$ = Intensity of inhibition of the $EM-n$, on isolated z -*Streptococcus* spp

$$Inb_{n-z}(\%) = \left[\frac{CEM_z - CEM_n}{CSGM_n} \right] \times 100$$

CEM_nSGM_i = Counting in treatment $EM-n$ vs isolate z -*Streptococcus* spp

CEM_n = Counting in treatment $EM-n$

$CSGM_z$ = Observed count for isolate z -*Streptococcus* spp. in the absence of $EM-n$

189

190 *Data analysis*

191 The obtained data were evaluated regarding the mathematical assumptions for parametric analysis.
 192 The analysis of variance (ANOVA) and means tests for the qualitative variables and regression
 193 analysis were performed for the quantitative variables, with significance level $\alpha = 0.05$.

194

195

196

197 **Results and discussion**


198

199 *Selection of isolates of Streptococcus mutans group*

200

201 All the isolates presented adherence in glass and HPA, however the selection for the next step was by
 202 the HPA assay. Fig. 3 expresses the intensity of Streptococcus spp. cells recovered from biofilms,
 203 developed by each HPA isolate, evidencing the existence of 4 statistically similar mean sets ($P \leq 0.05$),
 204 distinguished by Student's *t*-test.

205



206

207 **Fig. 3 - Intensity of bacterial cells, present in biofilms produced on crystals of HPA, in function**
 208 **of Streptococcus spp. strains obtained from the oral cavity of pre-school children. Bars =**
 209 **confidence interval ($\alpha = 0.05$).**

210 The C12VA isolate was selected for the category of high virulence, as of medium virulence the
 211 C04PD and as of low virulence the C17VA. The choice of the C04PD isolate was partially arbitrated
 212 by the presence of median density of adhered cells, combined with lower variance and the fact that it
 213 originates in the palatine face, since the other selected ones came from the vestibular face. The
 214 virulence properties of SGM are acid tolerance, the production of acids and the proteolytic activity,
 215 which allow the survival of the microorganism in the biofilm adapting to the environment, by means
 216 of adhesins, glycosyltransferases, extracellular polysaccharides and degradation of collagen of the
 217 substrate⁴⁵. As the isolates used had a difference in the capacity of biofilm production, one of the
 218 factors that may explain this variation may be the effectiveness of the glycosyltransferase (GTF)
 219 synthesized for each isolate. Once SGM isolates can secrete three types of glycosyltransferase, being
 220 that *GTF B* produces water insoluble glucans⁴⁰, to water-soluble *GTF D*⁴⁶ and soluble and water
 221 insoluble *GTF C* glucans⁴⁰. As the HPA crystals were washed in water before counts, the isolates that
 222 had as products of *GTF C* and *D*, therefore they would have released glucans soluble in water, may

223 have had entrained cells during the washing process, giving smaller counts. Venkitaraman et al.
224 (1995)⁴⁷, concluded that enzymes the *GTF B, C* and *D* influence the stability of the biofilm and that
225 the nature of the glucan produced can influence the adhesion of SMG in an experimental film.
226 Bacteria involved in periodontal diseases live in communities functionally organized and structured in
227 biofilm. The oral cavity presents several complex and continuously changing microenvironments, in
228 which microorganisms must rapidly adapt to survive⁴⁸. The biofilm growth promotes a gradual
229 decrease of oxygen concentration over time, favoring anaerobic and microaerophilic bacteria⁴⁹.
230 Strategies of formation of dental biofilm by *Streptococcus mutans* group has ecological determinant
231 function for the survival of these microorganisms, which may incite diseases such as dental caries and
232 infectious endocarditis⁵⁰⁻⁵¹.

233

234 *Physical and chemical attributes of crude extracts obtained*

235

236 Table 1 expresses the yield in function of the extraction method (EM) and the solvent used. The
237 highest yields were obtained in the cold extraction modes (4.2% with Ethyl Acetate) and by drag using
238 only solvents (5.56% with Butanol), without fractionation. Drag extraction (hot) with only and
239 fractional solvent were realized in the soxhlet, but in different ways. In the first the vegetal material is
240 renewed with each input of a solvent; thus, the processing makes possible a highly efficient extraction,
241 while in the fractionated with only cartridge of the vegetal material is used for the passage of the four
242 solvents (hexane, dichloromethane, ethyl acetate and butanol), in this way the exhaustion of the
243 vegetal material occurs, consequently the least drag of substance in the latter solvents. In cold
244 extraction, the process occurs at ambient temperature for a long period (days), under occasional
245 shaking and without renewal of the liquid extractor (static process). Therefore it does not lead to the
246 exhaustion of vegetal material, but occurs at the saturation of the liquid extractor or the establishment
247 of a balance between the extraction medium and the interior of the plant cell⁵². Soxhlet extraction has
248 demonstrated the best solvent extraction efficiency, results similar to other studies⁵³⁻⁵⁴. The results of
249 this work demonstrate that the extraction method, the solvent used and the temperature directly
250 influence the total yield of the extract, however it is necessary to take into account that many
251 substances are thermolabile and others may undergo irreversible structural changes at high
252 temperatures⁵⁴.

253

254

255

256

257

258 **Table 1 - Yield (% m/v) of the extracts obtained in each type of extraction of the bark of**
 259 ***Erythrina* spp.**

Solvent	Yield (% m/v)		
	Without heating extraction	With fractionated heating extraction	With heating solvent extraction only
Hexane	1,10	1,02	1,84
Dichloromethane	2,60	2,00	3,94
Ethyl acetate	4,20	1,84	4,32
Butanol	4,00	1,24	5,56

260

261 The results obtained in the phytochemical prospection of the 12 extracts used, they are represented in
 262 table 2. In the phytochemical analysis of the extracts of the bark of *Erythrina* spp the presence of
 263 tannin, flavonoid, resin and tripterpenos / steroids was verified. In studies with species of *Erythrina*
 264 spp. some authors corroborate the results found. The phytol substance of the class of terpenes was
 265 found in methanolic extract of dried flowers of the same species⁵⁵. Already flavonoids (alpinumioso
 266 and derrona) in hydroalcoholic extracts of the stalk⁵⁶. The negative result for alkaloids differ from
 267 results obtained by Almeida⁵⁷. Some authors report that tannins have inhibitory effects on fungi and
 268 bacteria.⁵⁷⁻⁵⁸ There are three hypotheses for the mechanism of antimicrobial action. The first
 269 hypothesis presupposes the inhibition of bacterial and fungal enzymes and / or the complexation of the
 270 substrates of these enzymes; the second would be the action of tannins on the cell membranes of
 271 microorganisms, modifying their metabolism. Finally, the third hypothesis mentions the complexation
 272 of tannins with metal ions, thus reducing the availability of these essential elements for the metabolism
 273 of microorganisms. The results show that each type of solvent dragged the metabolite by affinity for
 274 polarity. Hexane steroids and tripterpenes, dichloromethane flavonoids and steroid / tripterpenes, ethyl
 275 acetate flavonoids, tannins and tripterpenes and butanol flavonoids and tannins. Reports such as those
 276 obtained herein are reported in the literature.⁵⁹

277

278 **Table 2 - Secondary compounds diagnosed in extracts of *Erythrina* spp bark, depending on the**
 279 **extraction method and solvent used.**

Solvent extractor	Without heating extraction	With fractionated heating extraction	With heating solvent extraction only
Hexane	te	te	te
Dichloromethane	f; r; te	f; r; te	f; r; te
Ethyl acetate	f; r; t; te	f; r; t; te	f; r; t; te
Butanol	f; t	f; t	f; t

280 t-tannin; f-flavonoid; r-resin; te-triiterpene /steroid.

281 *Inhibitory concentrations of extracts on Streptococcus spp.*

282

283 Table 3 expresses the viable cell count values, recovered after submission to MS of *Erythrina* spp.,
284 Considering the concentrations capable of inhibiting the growth and causing the death of the SGM
285 population, in proportion $\geq 90\%$.

286 The selection strategy of SGM isolates, based on adherence-virulence in HPA, was shown to be
287 useful, but evidenced the existence of biochemical components not considered in our study model.
288 Thus, it was observed that, for extracts EM-2, EM-3, EM-6 and EM-10, the isolate selected as less
289 virulent (C17VA) was inhibited with lower extracts concentration than the more virulent (C12VA).
290 The opposite occurred for the extracts EM-1, EM-5 and EM-8, where this logic was reversed.
291 Suggesting that some of these EM act efficiently on the destabilization of the biofilm, without,
292 however, being lethal bacterial cells.

293 Cold extraction with butanol presented higher efficiency in the inhibition of the selected isolates.
294 Already in relation to the mode of extraction by drag, the use of the only solvent provided better
295 results than the sequential use of the solvents in the same sample. Although the presence of the same
296 substances in the phytochemical analysis was confirmed (Table 2) the levels of these substances were
297 distinct for the two methods in question. Regarding the extractive solvents, ethyl acetate,
298 dichloromethane and butanol were more efficient than hexane. The results demonstrated that Soxhlet
299 extraction using only solvent is the one with the highest yield, but the yield is not directly related to
300 the increase in total bioactive. Study conducted by Herzie et al. (2013), demonstrates significant
301 differences in the nature of the components And the amount thereof with respect to the extraction
302 method.⁶⁰ Numerous studies were carried out with the objective of determining the antimicrobial and
303 anti-adherent activity of various types of plant extracts against *Streptococcus mutans* group.⁶¹⁻⁶³ For
304 the purpose of inhibit or reduce the formation of the dental biofilm, bacterial growth, and
305 consequently the adhesion of microorganisms on the surface of the tooth.⁶⁴⁻⁶⁸ However, studies on
306 antimicrobial and anti-adherent activity of *Erythrina* extract are scarce in the national and international
307 literature. A study related to *Erythrina* spp. has the purpose of evaluate its anxiolytic and antimicrobial
308 effect, with other microorganisms.⁶⁸⁻⁶⁹ In the study, the presence of antimicrobial activity of the bark of
309 *Erythrina* spp. on the C17VA, C04PD and C12VA isolates and the broad reference strains: ATCC
310 25175 and ATCC 27392. The results showed that all isolates tested were sensitive to at least one of
311 *Erythrina* spp. (Table 3). There is a lot of divergence between the authors regarding the concentration
312 of the extract for prospecting of drugs.⁷⁰⁻⁷¹ Considering rigorous criteria for the evaluation of the
313 potential of EM for pharmaceutical purposes, we have chosen those suggested by Aligiannis and
314 collaborators (2001)⁷¹, in which an extract is considered a strong inhibitor $MIC \leq 500\mu\text{g.mL}^{-1}$,
315 moderate inhibitor $\geq 500\mu\text{g.mL}^{-1}$ $MIC \leq 1500\mu\text{g.mL}^{-1}$ and weak inhibitor: $MIC \leq 1500\mu\text{g.mL}^{-1}$. The
316 bactericidal concentrations (Suppression $\geq 90\%$ population) indicate that the best results were for the

317 inhibition of strain ATCC25175 (*S. mutans*) EM4, strain ATCC 27392 (*S. sobrinus*) EM2, EM4, EM6,
318 EM10 and EM11, for the isolate C17VA the extracts EM2, EM3, EM6 and EM10, none of the EM
319 was satisfactory in inhibiting the C04PDe C12VA isolates. However, the results showed that EM was
320 generally effective in reducing the population growth of SGM isolates at concentrations $\geq 750\mu\text{g.mL}^{-1}$.

321 Table 3 – Minimum Inhibitory and Bactericidal Concentrations capable to reducing *Streptococcus mutans* group populations to levels less or equal
322 than 90% in function of different preparations of extracts of *Erythrina* spp.

Extract Method ¹	<i>Streptococcus mutans</i> group Strains									
	ATCC 25175		ATCC 27392		C17VA		C04PD		C12VA	
	MIC ²	MBC ₉₀ ³	MIC ²	MBC ₉₀ ³	MIC ²	MBC ₉₀ ³	MIC ²	MBC ₉₀ ³	MIC ²	MBC ₉₀ ³
EM-1	≥750	≥3000	≥375	≥750	≥750	≥1500	WI	WI	≥1500	≥1500
EM-2	≥1500	≥3000	≥187,5	≥187,5	≥187,5	≥187,5	WI	WI	≥187,5	≥750
EM-3	≥1500	≥3000	≥375	≥750	≥375	≥375	≥750	≥1500	≥187,5	≥750
EM-4	≥187,5	≥375	≥187,5	≥375	≥750	≥750	≥750	≥750	≥375	≥750
EM-5	WI	WI	≥1500	≥1500	≥3000	≥3000	WI	WI	≥1500	≥1500
EM-6	≥350	≥750	≥375	≥375	≥187,5	≥375	≥187,5	≥750	≥187,5	≥750
EM-7	≥750	≥1500	≥375	≥750	≥375	≥1500	≥375	≥1500	≥750	≥1500
EM-8	WI	WI	≥1500	≥3000	≥3000	≥3000	≥3000	≥3000	≥1500	≥1500
EM-9	WI	WI	≥3000	≥3000	≥3000	≥3000	WI	WI	≥3000	≥3000
EM-10	≥1500	≥3000	≥187,5	≥375	≥93,75	≥375	≥375	≥750	≥187,5	≥750
EM-11	≥750	≥1500	≥375	≥375	≥375	≥750	≥375	≥750	≥187,5	≥750
EM-12	≥750	≥3000	≥375	≥750	≥750	≥1500	≥750	≥1500	≥375	≥1500

323 ¹EM-1: Hexane and without heating extraction; EM-2: Dichloromethane and without heating extraction; EM-3: Ethyl acetate and without heating extraction; EM-4: Butanol and without heating
 324 extraction; EM-5: Hexane and with fractionated heating extraction; EM-6: Dichloromethane and with fractionated heating extraction; EM-7: Ethyl acetate and with fractionated heating
 325 extraction; EM-8: Butanol and with fractionated heating extraction; EM-9: Hexane and with heating solvent extraction only; EM-10: Dichloromethane and with heating solvent extraction only;
 326 EM-11: Ethyl acetate and with heating solvent extraction only; EM-9: Butanol and with heating solvent extraction only.

327 ²Minimal Inhibitory Concentration ($\mu\text{g.mL}^{-1}$)

328 ³ Minimal Bactericidal Concentration capable to reducing $\geq 90\%$ of cell counting ($\mu\text{g.mL}^{-1}$)

329 WI– Inhibitory effect absent

330 *Effect of the extract on biofilm production on hydroxyapatite crystals*

331

332 The application of the extracts in a curative mode, therefore after the previous colonization of
333 HPA crystals by SGM resulted in exclusion of all the populations of the isolates under study.
334 Table 4 expresses the resistance to biofilm disorder, formed by the different SGM isolates when
335 submitted to contact with the EM of *Erythrina* spp preventively. Considering the inhibition
336 indices, it is possible to state that the best results were for the inhibition of ATCC 27392 strain
337 (*S. sobrinus*) extracts EM2, EM3, EM4, EM6, EM7, EM10 and EM11, for the C17VA isolate
338 extracts EM2, EM3 EM10, EM10, EM10 and EM12, for the C04PD isolate the extracts EM4,
339 EM6, EM7, EM10 and EM11, for the C12VA isolate the extracts EM10 and EM11, none EM
340 was satisfactory in inhibiting strain ATCC 25175 (*S. mutans*) in a preventive mode. Confirming
341 as previously observed that the selection of the isolates by the virulence factor was useful in the
342 study of the antimicrobial properties of plant extracts. The concentration of $1500\mu\text{g.mL}^{-1}$ more
343 effective in preventing biofilm formation by SGM, however, strain ATCC 27392 (*S. sobrinus*)
344 and C17VA isolate were sensitive at concentrations lower than $1500\mu\text{g.mL}^{-1}$.

345

346

347

348

349

350

351

352

353

354

355

356 Table 4 –Assessment of *Streptococcus mutans* group populations in biofilm structured on hydroxyapatite (HAP), expressed as Log₁₀, and Inhibition Rate (IR), expressed as
357 percentage, in function of different preparations of extracts of *Erythrina* spp. applied preventively.

Extract µg.mL ⁻¹		<i>Streptococcus mutans</i> group Strains									
		ATCC 25175		ATCC 27392		C17VA		C04PD		C12VA	
		Log Count ²	IR ³ (%)	Log Count ²	IR ³ (%)	Log Count ²	IR ³ (%)	Log Count ²	IR ³ (%)	Log Count ²	IR ³ (%)
EM-1	1500	NR	-	7.39±0.14	0.00±1.28	NR	---	NR	---	9.96±0.00	0.00±1.53
	750	NR	-	9.96±0.00	0.00±2.74	NR	---	NR	---	9.96±0.00	0.00±1.53
	375	NR	-	9.96±0.00	0.00±2.74	NR	---	NR	---	9.96±0.00	0.00±1.53
EM-2	1500	NR	-	0.00±0.00	100±0.00	0.00±0.00	100±0.00	NR	---	8.41±0.11	6.17±1.52
	750	NR	-	0.00±0.00	100±0.00	5.82±0.22	0.00±0.00	NR	---	9.96±0.00	0.00±1.53
	375	NR	-	9.96±0.00	0.00±2.74	9.96±0.00	0.00±0.00	NR	---	9.96±0.00	0.00±1.53
EM-3	1500	NR	---	0.00±0.00	100±0.00	0.00±0.00	100±0.00	3.16±0.08	57±0.29	8.43±0.00	7.71±1.45
	750	NR	---	9.96±0.00	0.00±2.49	6.27±0.13	0.00±0.00	9.96±0.00	0.00±2.55	9.96±0.00	0.00±1.53
	375	NR	---	9.96±0.00	0.00±2.74	9.96±0.00	0.00±0.00	9.96±0.00	0.00±2.55	9.96±0.00	0.00±1.53
EM-4	1500	9.96±0.00	0.00±2.44	0.00±0.00	100±0.00	0.00±0.00	100±0.00	0.00±0.00	100±0.00	8.10±0.11	11.28±0.00
	750	9.96±0.00	0.00±0.00	6.87±0.15	0.00±3.47	0.00±0.00	100±0.00	7.24±0.03	0.00±1.74	9.96±0.00	0.00±0.00
	375	9.96±0.00	0.00±1.67	9.96±0.00	0.00±2.74	0.00±0.00	100±0.00	9.96±0.00	0.00±2.55	9.96±0.00	0.00±0.00
EM-5	1500	NR	---	7.06±0.04	0.00±1.53	NR	---	NR	---	9.96±0.00	0.00±2.05
	750	NR	---	9.96±0.00	0.00±1.53	NR	---	NR	---	9.96±0.00	0.00±1.67
	375	NR	---	9.96±0.00	0.00±1.53	NR	---	NR	---	9.96±0.00	0.00±1.67
EM-6	1500	7.41±0.07	0.00±2.05	0.00±0.00	100±0.00	0.00±0.00	100±0.00	0.00±0.00	100±0.00	8.41±0.06	7.91±1.27
	750	9.96±0.00	0.00±1.67	7.29±0.03	0.00±2.36	0.00±0.00	100±0.00	6.65±0.41	10.5±6.21	9.96±0.00	0.00±1.53
	375	9.96±0.00	0.00±1.67	9.96±0.00	0.00±2.74	9.96±0.00	0.00±0.00	9.96±0.00	0.00±2.55	9.96±0.00	0.00±1.53
EM-7	1500	NR	---	0.00±0.00	100±0.00	0.00±0.00	100±0.00	0.00±0.00	100±0.00	8.26±0.05	9.58±0.76
	750	NR	---	9.96±0.00	0.00±2.74	6.47±0.08	0.00±0.00	9.96±0.00	0.00±2.55	9.96±0.00	0.00±1.53
	375	NR	---	9.96±0.00	0.00±2.74	9.96±0.00	0.00±0.00	9.96±0.00	0.00±2.55	9.96±0.00	0.00±1.53
EM-8	1500	NR	-	NR	---	0.00±0.00	-	NR	-	8.43±0.03	7.69±1.04
	750	NR	-	NR	---	7.14±0.15	-	NR	-	9.96±0.00	0.00±1.53
	375	NR	-	NR	---	9.96±0.00	-	NR	-	9.96±0.00	0.00±1.53
EM-9	1500	NR	-	7.40±0.05	0.00±1.42	NR	-	NR	-	NR	-
	750	NR	-	9.96±0.00	0.00±2.74	NR	-	NR	-	NR	-
	375	NR	-	9.96±0.00	0.00±2.74	NR	-	NR	-	NR	-
EM-10	1500	NR	-	0.00±0.00	100±0.00	0.00±0.00	100±0.00	0.00±0.00	100±0.00	0.00±0.00	100±0.00
	750	NR	-	7.17±0.06	0.00±2.77	6.48±0.22	0.00±0.00	9.96±0.00	0.00±2.55	8.18±0.07	10.39±1.78
	375	NR	-	9.96±0.00	0.00±2.74	9.96±0.00	0.00±0.00	9.96±0.00	0.00±2.55	9.96±0.00	0.00±1.53
EM-11	1500	6.65±0.00	0.00±0.88	0.00±0.00	100±0.00	0.00±0.00	100±0.00	0.00±0.00	100±0.00	0.00±0.00	100±0.00
	750	9.96±0.00	0.00±1.67	0.00±0.00	100±0.00	9.96±0.00	0.00±0.00	9.96±0.00	0.00±2.55	7.61±0.00	19.91±1.78
	375	9.96±0.00	0.00±1.67	9.96±0.00	0.00±2.74	9.96±0.00	0.00±0.00	9.96±0.00	0.00±2.55	9.96±0.00	0.00±1.53
EM-12	1500	NR	-	6.42±0.24	0.00±2.21	0.00±0.00	100±0.00	6.12±0.22	16.67±3.16	8.31±0.04	8.98±1.30
	750	NR	-	9.96±0.00	0.00±2.74	0.00±0.00	100±0.00	9.96±0.00	0.00±2.55	9.96±0.00	0.00±1.53
	375	NR	-	9.96±0.00	0.00±2.74	7.42±0.04	0.00±0.00	9.96±0.00	0.00±2.55	9.96±0.00	0.00±1.53

358 EM-1: Hexane and without heating extraction; EM-2: Dichloromethane and without heating extraction; EM-3: Ethyl acetate and without heating extraction; EM-4: Butanol and without heating extraction; EM-5: Hexane and with fractionated heating
359 extraction; EM-6: Dichloromethane and with fractionated heating extraction; EM-7: Ethyl acetate and with fractionated heating extraction; EM-8: Butanol and with fractionated heating extraction; EM-9: Hexane and with heating solvent extraction
360 only; EM-10: Dichloromethane and with heating solvent extraction only; EM-11: Ethyl acetate and with heating solvent extraction only; EM-9: Butanol and with heating solvent extraction only.¹Mean to Log₁₀ of Bacterial Count; Bars = Confidence
361 Interval ($\alpha=0,05$; $n=3$); ²Percentual of Inhibition (%) at control treatment; Bars = Confidence Interval ($\alpha=0,05$; $n=3$); NR – Not rated.

* Autor para correspondência: sergio.nobre@unimontes.br

REFERENCES

1. Featherstone JDB. The science and practice of caries prevention. J Am Dent Assoc. 2000; 131: 887-899.
2. Quivey RG, Kuhnert WL, Hahn K. Genetics of acid adaptation in oral streptococci. Crit. Rev. Oral Biol. Med. 2001; 12: 301-314.
3. Bowen WH. Do we need to be concerned about dental caries in the coming millennium? Crit Rev Oral Biol Med. 2002; 13:126–131.
4. Lemos JA, Abranches J, Burne RA. Responses of cariogenic streptococci to environmental stresses. Curr Issues Mol. Biol.2005;7: 95-108.
5. Paes Leme AF, Koo H, Bellato CM, Bedi G, Cury JA. The role of sucrose in cariogenic dental biofilm formation: new insight. J Dent Res. 2006; 85(10):878-887.
6. Whittaker CJ, Klier CM, Kolenbrander PE. Mechanisms of adhesion by oral bacteria. Annu Ver Microbiol. 1996; 50: 513-552.
7. Kolenbrander PE. Oral microbial communities: biofilms, interactions, and genetic systems. Annu Rev Microbiol. 2000; 54: 413-437.
8. Nakano K, Ooshima T. Serotype classification of *Streptococcus mutans* and its detection outside the oral cavity. Future Microbiol. 2009; 4(7):891-902.
9. Loesche WJ. Role of *Streptococcus mutans* in human dental decay. Microbiol Rev.1986; 50:353 – 380.
10. Whiley RA, Beighton D. Current classification of the oral streptococci. Oral Microbiol. Immunol. 1998; 13(4): 195-216.
11. Nomura R, Nakano K, Nemuto H, Fujita K, Inagaki S, Takahashi T, et al. Isolation and characterization of *Streptococcus mutans* in heart valve and dental plaque specimens from a patient with infective endocarditis. J Med Microbiol. 2006;55:1135 -40
12. Koneman EW, Allen SD, Janda WM, Schreckenberger PC, Winn JrWC. Diagnóstico microbiológico- 5 ed. Rio de Janeiro. MEDSI-Editora Médica e Científica Ltda;2001.
13. Leite B, Pascholati SF, Kitajima EW, Ishida ML. Mecanismos de adesão de bactérias e fungos às plantas hospedeiras. Revisão Anual de Patologia de Plantas. 2001; 9: 1-41.
14. Cvitkovitch DG, Yung-Hua L, Ellen RP. Quorum sensing and biofilm formation in streptococcal infections. J. Clin. Invest. 2003; 112:1626-1632.
15. Jensen M E, Schachtele CF. Plaque pH measurements by different methods on the buccal and approximal surfaces of human teeth after a sucrose rinse. J. Dent. Res. 1983; 62:1058-1061.
16. Jardim Jr EG, Pedrini D, Xavier EA, Jardim PS. Eficácia do listerine sobre a placa. RGO. 1998; 46: 70-78.
17. Castro SL. “In vivo” Study efficacy of antiseptics on microaerobic microorganisms of the oral cavity. RevDent. 2001; 1: 1-9.,
18. Ooshima T, Matsumura M, Hoshino T, Kawabatas T, Soube S, Fujiwara T. Contributions of three glycosyltransferases to sucrose-dependent adherence of *Streptococcus mutans*. J. Dent Res. 2001; 80: 1672-1677.
19. Drumond MRS, Castro RD, Almeida RVD, Pereira MSV, Padilha WWN. Estudo comparativo in vitro da atividade antibacteriana de produtos fitoterápicos sobre bactérias cariogênicas. Pesq Bras OdontopedClin Integr. 2004; 4(1):33-38.
20. Borba AM, Macedo M, Walter LRF. Alternative dentistry with medicinal plants in Chapada dos Guimarães - MatoGrosso, Brazil. South Braz Dent J. 2008; 5(1):43-49.

21. Palombo E. Traditional medicinal plant extracts and natural products with activity against oral bacteria: potential application in the prevention and treatment of oral diseases. Oxford J. 2009; 1-26.
22. Cleff MB. et al. Perfil de suscetibilidade de leveduras do gênero *Candida* isoladas de animais ao óleo essencial de *Rosmarinu officinalis*L. Rev. Bras. plantas medicinais. 2012;14(1):43-49.
23. Souza WM A. et al. Avaliação in vitro do extrato hidroalcoólico (EHA) de alecrim pimenta (*Lippia sidoides* Cham.) sobre o desenvolvimento de ovos de nematódeos gastrointestinais (*Trichostrongylidae*). Rev. bras. plantas medicinais. 2010; 12(3): 278-281.
24. Carelli G et al. Avaliação preliminar da atividade antimicrobiana do extrato de erva-mate (*Ilexparaguariensis* A. St. - Hil.) obtido por extração com CO₂ supercrítico. Rev. bras. plantas medicinais. 2011;13(1):110-115.
25. Leitão F, Leitão SG, Fonseca-Krueel, VS, Silva IM, Martins K. Medicinal plants traded in the open-air markets in the State of Rio de Janeiro, Brazil: overview on their botanical diversity and toxicological potential. Rev. Bras. Farmacogn.,2014; 24: 225-247.
26. De Bona AP et al. Estudo fitoquímico e análise mutagênica das folhas e inflorescências de *Erythrina mulungu* (Mart. ex Benth.) através do teste de micronúcleo em roedores. Rev. bras. plantas medicinais. 2012; 14(2):44-351.
27. Yunes RA, Cechinel Filho V. Breve análise histórica de plantas medicinais: sua importância na atual concepção de fármaco segundo os paradigmas ocidental e oriental. In: Yunes RA, Calixto JB. Plantas medicinais sob a óptica da química medicinal moderna. Chapecó : Argos; 2001. 17-46.
28. Cechinel VF, Yunes R A. Estudo químico de plantas medicinais orientado para análise biológica. Obtenção, determinação e modificação estrutural de compostos bioativos. In: Yunes R A, Calixto JB. (Eds.). Plantas medicinais sob a ótica da química medicinal moderna. Santa Catarina: Argos. 2001; 48-75.
29. Soejarto DD. Biodiversity prospecting and benefit sharing: perspectives from the field. J. Ethnopharmacol.1996; 51:1-15.
30. Savoia D. Plant-derived antimicrobial compounds: alternatives to antibiotics. Future Microbiol. 2012; 7: 979-90.
31. Guinoiseau, E et al. Cellular effects induced by *Inulagraveolens* and *Santolinacorsica* essential oils on *Staphylococcus aureus*. European Journal of Clinical Microbiology & Infectious Diseases. 2010; 29(7): 873-9.
32. Gurib-Fakim, A. Medicinal plants: traditions of yesterday and drugs of tomorrow. Molecular Aspects of Medicine. 2006; 27:1-93.
33. *Erythrina* in Flora do Brasil 2020 em construção. Jardim Botânico do Rio de Janeiro. Disponível em: <<http://reflora.jbrj.gov.br/reflora/floradobrasil/FB105155>>. Acesso em: 30 Mar. 2017
34. Onusic GM, Nogueira RL, Pereira AMS, Viana MB. Effect of acute treatment with a water-alcohol extract of *Erythrina mulungu* on anxiety-related responses in rats. Braz J MedBiol Res. 2002; 35: 473–477.
35. Roberts M. Indigenous Healing Plants, Southern Books, Pretoria, South Africa. 1990.
36. Hutchings A, Scott AH, Lewis G, Cunningham AB. Medicinal Plants: An Inventory, University of Natal Press, Pietermaritzburg, South Africa. 1996.
37. Burkill H. The useful plants of West Tropical Africa. London: Royal Botanic Garden Kew; 1985.
38. Vasconcelos SMM, Lima NM, Sales GTM, Cunha GMA, Aguiar LMV, et al. Anticonvulsant activity of hydroalcoholic extracts from *Erythrina velutina* and *Erythrina mulungu*. J Ethnopharmacol. 2007; 110: 271–274.

39. Vasconcelos SMM, Oliveira GR, Carvalho MM, Rodrigues ACP, Silveira ER, et al. Antinociceptive activities of the hydroalcoholic extracts from *Erythrina velutina* and *Erythrina mulungu* in mice. *Biol Pharm Bull*. 2003; 26: 946–949.
40. Kim TH *et al.*, 2,4,6- tris(methoxymethoxy) chalcone (TMMC) attenuates the severity of cerulein-induced acute pancreatitis and associated lung injury,” *American Journal of Physiology: Gastro intestinal and Liver Physiology*. 2011; 301(4): 694–706.
41. Fukushima K, Ikeda T, Kuramitsu HK. Expression of *Streptococcus mutans* glucosyltransferase genes in *Streptococcus milleri*. *Infect Immun*. 1992; 60: 2815-2822.
42. Matos FJA. Introdução à fitoquímica experimental. Fortaleza: Ed. da UFC. 2008; 148.
43. CLSI. Clinical and Laboratory Standards Institute (CLSI). Metodologia dos testes de sensibilidade a agentes antimicrobianos por diluição para bactérias de crescimento aeróbico: Norma aprovada – sexta edição – M7-A6 2003.
44. ISO 7218. Microbiology of food and animal feeding stuffs – General requirements and guidance for microbiological examination, 3^a ed. The International Organization for Standardization, 2007.
45. Hamada S, Slade HD. Biology, immunology and cariogenicity of *Streptococcus mutans* and dental caries prevention. *J Dent Res* 1980;63:407–411.
46. Hanada, N, Kuramitsu, H.K. Isolation and characterization of the *Streptococcus mutans* *gtf d* gene, coding for primer-dependent soluble glucan synthesis. *Infect Immun*. 1989; 57: 2079- 2085.
47. Venkitaraman, AR, Vacca-Smith AM, Kopec LK, Bowen WH. Characterization of glucosyltransferase B, Gtf C, and Gtf D in solution and in the surface of hydroxyapatite. *J Dent Res*. 1995; 74(10): 1695-1701.
48. Barbosa BMC *et al.*. Pacientes especiais: avaliação da contaminação microbiana e de métodos de desinfecção de escovas dentais. *Pesqui. Odontol. Bras.*, São Paulo. 2008; 17:180.
49. Lima JEO. Cárie dentária: um novo conceito. *R Dental Press OrtodonOrtop Facial*. 2007; 12 (6): 119-130.
50. Marsh PD. Dental plaque as a microbial biofilm. *Caries Res*. 2004; 38: 204-211.
51. Pant S, Patel NJ, Deshmukh A, Golwala H, Patel N, Badheka A, *et al.* Trends in infective endocarditis incidence, microbiology, and valve replacement in the United States from 2000 to 2011. *J Am CollCardiol*. 2015; 65(19):2070-6.
52. Banas JA, Vickerman MM. Glucan-binding proteins of the oral *streptococci*. *CritVer Oral Biol Med*. 2003;14: 89–99.
53. Karabegović IT. *et al.* The effect of different extraction techniques on the composition and antioxidant activity of cherry laurel (*Prunus laurocerasus*) leaf and fruit extracts. *Industrial Crops and Products*. 2014; 4:142- 148.
54. Tiwari P. *et al.* Phytochemical screening and Extraction: A Review. *Internationale Pharmaceutica Scientia*. 2011; 1(1):98-106.
55. Simões CMO, Schenkel EP, Gosmann G, Mello JCP, Mentz LA, Petrovick PR. *Farmacognosia: da planta ao medicamento*. 6.ed. Porto Alegre: Editora da UFRGS: Florianópolis: Editora da UFSC, 2010. 1104.
56. Erasto P, Bojase-Moleta G, Majinda RRT. Antimicrobial and antioxidant flavonoids from the root wood of *Bolusanthus speciosus*. *Phytochemistry*. 2004; 65(7):875-80.
57. Juma BF, Majinda RRT. Erythraline alkaloids from the flowers and pods of *Erythrina lysistemon* and their DPPH radical scavenging properties. *Phytochemistry*. 2004; 65 (10): 1397-404.
58. Almeida EE. Caracterização farmacognóstica da espécie *Erythrina falcata* Benth., Fabaceae. *Brazilian Journal of Pharmacognosy*. 2010; 20 (1): 100-5.

59. Plaza CV, Silva GH, Cafêu MC, Araujo AR, Lopes MNE, Bolzani VS. Estudo fitoquímico dos galhos de *Erythrina*. 28ª Reunião Anual da Sociedade Brasileira de Química, PN-154, Poços de Caldas. 2005.
60. Herzi N et al. Comparison of different methods for extraction from *Tetraclinis articulata*: yield, chemical composition and antioxidant activity. *Food Chemistry*. 2013; 141(4): 3537-3545.
61. Sanches ACC. et al. Antioxidant and antifungal activities of extracts and condensed tannins from *Stryphnodendron bovatum* Benth. *Rev. Bras. Cienc. Farm.* [online]. 2005;41(1):101-107.
62. Pereira JV, Pereira MSV, Sampaio FC. Efeito antibacteriano e antiaderente *in vitro* do extrato da *Punica granatum* Linn. sobre microrganismos do biofilme dental. *Ver Bras Farmacogn.* 2006;16: 88-93.
63. Linke HAB, Legeros RZ. Black tea extract and dental caries formation in hamsters. *Int J Food Sci Nutr.* 2003;54: 89–95.
64. Ghaemi A, Nazari R, Hamdi K, Ordouzadeh N, Amirmozafari N, Hassani A S. Volatile components of *Camélia sinensis* inhibit growth and biofilm formation of oral *Streptococci in vitro*. *Pakistan J BiolSci.* 2008; 11(10): 1336-1341.
65. Rodrigues E, Tabach R, Galduróz JCF, Negri G. Plants with possible anxiolytic and/or hypnotic effects indicated by three Brazilian cultures – Indians Afro-Brazilians, and river-dwellers. *Studies in Natural Products Chemistry*. 2008; 35:549-595.
66. Tsai PJ, Tsai TH, Ho SC. *In vitro* inhibitory effects of rosemary extracts on growth and glucosyltransferase activity of *Streptococcus sobrinus*. *Food Chem.* 2007; 105: 311-316.
67. Onusic GM, Nogueira RL, Pereira AMS, Flausino OA, Viana MB. Effects of chronic treatment with a water-alcohol extract from *Erythrina mulungu* on anxiety-related responses in rats. *BiolPharm Bull.* 2003; 26: 1538–1542.
68. Onusic GM, Nogueira RL, Pereira AMS, Viana MB. Effect of acute treatment with a water-alcohol extract of *Erythrina mulungu* on anxiety-related responses in rats. *Braz J MedBiol Res.* 2002; 35(4): 473–477.
69. Virtuosos S, et al. Estudo preliminar da atividade antibacteriana das cascas de *Erythrina velutina* Willd., Fabaceae Leguminose). *Revista Brasileira de Farmacognosia.* 2005; 15(2): 137-142.
70. Holetz FB, Pessini GL, Sanches NR, Cortez DA. Screening of some plants used in the Brazilian folk medicine for the treatment of infectious diseases. *Mem Inst Oswaldo Cruz.* 2002; 97(7):1027-31.
71. Aligiannis N. et al. Composition and antimicrobial activity of the essential oil of two *Origanum* species. *J. Agric Food Chem.*, 40: 4168–70, 2001.

4 CONCLUSÕES

- Os extratos de *Erythrina* spp. apresentaram atividade antimicrobiana e antiaderente frente aos isolados de SGM.
- A seleção de isolados de SGM baseado no fator de virulência é eficaz para estudos relacionados à ação inibitória de extratos vegetais.
- Os extratos de *Erythrina* spp. nas concentrações superiores a $750 \mu\text{g.mL}^{-1}$, mostraram inibição significativa ao crescimento de alguns isolados de SGM.
- Os extratos de *Erythrina* spp. na concentração $1500 \mu\text{g.mL}^{-1}$, mostraram que são capazes de desestruturar biofilmes dos isolados de SGM.
- Extratos de *Erythrina* spp. podem ser uma fonte valiosa para a descoberta de novas moléculas bioativas empregadas para inibição do crescimento de *Streptococcus* do grupo *mutans* e conseqüentemente na formação de biofilme dentário.

REFERÊNCIAS

1. Fejerskov O, Kidd E. Cárie dentária: a doença e seu tratamento clínico. 1. ed. São Paulo: Santos, 2005.
2. Bowen WH. Do we need to be concerned about dental caries in the coming millennium? Crit Rev Oral Biol Med. 2002; 13:126–131.
3. Paes Leme AF, Koo H, Bellato CM, Bedi G, Cury JA. The role of sucrose in cariogenic dental biofilm formation: new insight. J Dent Res. 2006; 85(10):878-887.
4. Hamada S, Slade HD. Biology, immunology and cariogenicity of *Streptococcus mutans* and dental caries prevention. J Dent Res. 1980; 63:407–411.
5. Loesche WJ. Role of *Streptococcus mutans* in human dental decay. Microbiol Rev. 1986; 50:353 – 380.
6. Keyes PH. Recent advances in dental research. Bacteriology. Int Dent J, London. 1962; 12(4): 443-464.
7. Hausen H. Caries prediction: state of the art. Community Dent Oral Epidemiol. 1997; 25(1): 87- 96.
8. Lima JEO. Cárie dentária: um novo conceito. R Dental Press OrtodonOrtop. Facial. 2007; 2(6): 119-130.
9. Whaley RA, Beighton D. Current classification of the oral streptococci. Oral Microbiol. Immunol. 1998; 13(4): 195-216.
10. Newbrun E. Cariology. Baltimore: Williams & Wilkins. 1978; 326.
11. Ismail AI, Sohn W, Tellez M, Willem JM, Betz J, Lepkowski J. Risk indicators for dental caries using the International Caries Detection and Assessment System (ICDAS). Community Dent Oral Epidemiol. 2008; 36:55-68.
12. Davidoff DC, Abdo RC, Silva SM. Prevalência de cárie precoce na infância. Pesq Bras Odontopediatr Clin Integr. 2005; 5: 215-21.
13. Peres KG, Bastos JR, Latorre M R. Severidade de cárie em crianças e relação com aspectos sociais e comportamentais. Rev Saude Publica. 2000; 34: 402-8.
14. De Lorenzo, J. L. Microbiologia para o estudante de odontologia. São Paulo: Atheneu, 2004.

15. Marsh, PD. Microbial aspects of dental plaque and dental caries. *Dent Clin North Am.* 1999; 43.
16. Marsh P, Martin MV. *Microbiologia Bucal*. Trad. 4ª ed. São Paulo: Livraria Santos; 2005.
17. Köhler B, Birkhed D, Olsson S. Acid production by human strains of *Streptococcus mutans* and *Streptococcus sobrinus*. *Caries Research.* 1995; 29(5): 402- 406.
18. Sullivan A. Number of mutans streptococci or lactobacilli in a total dental plaque sample does not explain the variation in caries better than the numbers in stimulated whole saliva. *Community Dent Oral Epidemiol.* 1996; 24(3): 159-163.
19. Da-Hong Lee *et al.*. Inhibitory effect of *Aralia continentalis* on the cariogenic properties of *Streptococcus mutans*. *Journal of Ethnopharmacology.* 2011; 137(2): 979-84.
20. Featherstone JDB. The science and practice of caries prevention. *J Am Dent Assoc* 2000; 131: 887-99.
21. Loesche WJ, Lopatin DE, Stoll J, Poperin N, Hujoel PP. Comparison of various detection methods for periodontopathic bacteria: can culture be considered the primary reference standard? *J. Clin. Microbiol.* 1992; 30: 418–426.
22. Banas JA, Vickerman MM. Glucan-binding proteins of the oral *streptococci*. *Crit Ver Oral Biol Med.* 2003; 14:89–99.
23. Nakano K, Ooshima T, Serotype classification of *Streptococcus mutans* and its detection outside the oral cavity. *Future Microbiol.* 2009; 4(7): 891-902.
24. Burne RA. Oral streptococci: products of their environment. *J Dent Res, Chicago.* 1998; 77: 445-452.
25. Sasaki, H.; Matsumoto, M.; Tanaka, T.; Maeda, M.; Nakai, M.; Hamada, S. Anti bacterial activity of polyphenol components in oolong tea extract against *Streptococcus mutans*. *Caries Res.* 2004; 38 : 2–8.
26. Lemos JA, Abranches J, Burne RA. Responses of cariogênico streptococci to environmental stress. *Curr Issues Mol Biol, Norwich.* 2005; 7(1): 95-107.
27. Jenkinson HF, Lamont RJ. Oral microbial communities in sickness and in health. *Trends Microbiol.* 2005; 13(12):589-95.
28. Pant S, Patel NJ, Deshmukh A, Golwala H, Patel N, Badheka A, et al. Trends in infective endocarditis incidence, microbiology, and valve replacement in the United States from 2000 to 2011. *J Am Coll Cardiol.* 2015; 65(19): 2070-6.

29. Kuramitsu HK. Virulence factor of mutans streptococci: role of molecular genetics. *Crit Rev Oral BiolMedv.* 1993; 4:159-176.
30. Mcneill K, Hamilton IR. Acid tolerance response of biofilm cells of *Streptococcus mutans*. *FEMS MicrobiolLett.* 2003; 221: 25-30.
31. Montanaro L, Campoccia D, Rizzi S, Donati ME, Breschi L, PratiC, *et al.* Evaluation of bacterial adhesion of *Streptococcus mutans* on dental restorative materials. *Biomaterials.* 2004; 25: 4457-4463.
32. Abdus SM, Matsumoto N, Matin K, Tsuha Y, Nakao R, Hanada N, Sen- PukuH. Establishment of an animal model using recombinant NOD. B10. D2 mice to study initial adhesion of oral streptococci. *Clinical and Diagnostic. Laboratory Immunology.* 2004;11: 379–386.
33. Gaines S, James TC, Folan M, Baird AW, O’farrelly CO. A novel spectro fluorometric micro assay for *Streptococcus mutans* adherence to hydroxylapatite. *Journal of Microbiological Methods* (in press). 2003.
34. Grönroos L. Quantitative and Qualitative Characterization of Mutans Streptococci in Saliva and in the Dentition. Helsinki, 2000. 80 f. Dissertação Acadêmica. Department of Pedodontics and Orthodontics, Institute of Dentistry, University of Helsinki and Department of Oral and Maxillofacial Diseases, Helsinki University Central Hospital.
35. Kolenbrander PE. Oral microbial communities: biofilms, interactions, and genetic systems. *Annu Rev Microbiol.* 2000; 54: 413-437.
36. Yamashita Y, Bowen WH, Burne RA, Kuramitsu HK. Role of the *Streptococcus mutans* gft genes in caries induction in the specific-pathogen-free rat model. *Infect Immun,* Oxford. 1993; 61: 3811-3817.
37. Hayacibara MF, Koo H, Rosalen PL, Duarte S, Franco EM, Browen WH, Ikegaki M, Cury JA. In vitro and vivo effects of isolated fractions of Brazilian propolis on caries development. *J Ethnopharmacol.*1995; 101: 110-115.
38. Whiley RA, Beighton D. Current classification of the oral streptococci. *Oral Microbiol Immunol.* 1998; 13(4):195-216.
39. Linke, HAB, Legeros RZ. Black tea extract and dental caries formation in hamsters. *Int J Food SciNutr.* 2003; 54: 89–95.
40. Jensen ME, Schachtele, CF. Plaque pH measurements by different methods on the buccal and approximal surfaces of human teeth after a sucrose rinse. *J. Dent. Res.* 1993; 62: 1058-1061.
41. Quivey RG, Kuhnert WL, Hahn K. Genetics of acid adaptation in oral streptococci. *Crit. Rev. Oral Biol. Med.* 2001; 12: 301-314.

42. Battin TJ, Sloan WT, Kjelleberg S, Head IM, Curtis TP, Eberl L. Microbial landscapes: paths to biofilm research. *Nat. Rev. Microbiol.* 2007; 5: 76-81.
43. Alves PM, Pereira JV, Higino JS, Pereira MSV, Queiroz LMG. Atividade antimicrobiana e antiaderente *in vitro* da aroeira-do-sertão sobre o biofilme dental. *RBO.*2006; 63: 271-274.
44. Brozen R, Bachrach G, Bronshteyn M, Gedalia I, Steinberg D. The Role of fructans on dental biofilm formation by *Streptococcus sobrinus*, *Streptococcus mutans*, *Streptococcus gordonii* and *Actinomyces viscosus*. *FEMS Microbiol Lett* 2001; 195(2): 205-210.
45. Hall-Stoodley L, Costerton JW, Stoodley L. Bacterial biofilm: from the nature environment to infectious diseases. *Nat. Rev. Microbiol.* 2004; 2: 95-108.
46. Lindsay D, Von-Holy A. Bacterial biofilm within the clinical setting: what healthcare professionals should know. *Journal of Hospital Infection.* 2006; 64: 313-325.
47. Kumar CG, Anand SK. Significance of microbial biofilms in food industry: a review. *International Journal of Food Microbiology.* 1998; 42: 9-27.
48. Braga MM, Mendes FM, Imparato JCP. A doença Cárie Dentária. In: Imparato JCP, Raggio DP, Mendes FM. Selantes de fossas e fissuras: quando como e por quê? 1. ed. São Paulo: Livraria Santos Editora, 2008.
49. Whittaker CJ, Klier CM, Kolenbrander PE. Mechanisms of adhesion by oral bacteria. *Annu Ver Microbiol.* 1996; 50: 513-552.
50. Tenuta, LMA, Lima JEO, Cardoso CL, Tabchoury CPM, Cury, JA. Effect of period of plaque accumulation and salivary factors on enamel demineralization and plaque composition *in situ*. *Pesqui Odontol Bras.* 2003; 17(4): 326-331.
51. Thylstrup A, Fejerskov O. *Cariologia clínica.* 2.ed. São Paulo: Santos; 1995.
52. Uzeda, M. *Microbiologia Oral.* Rio de Janeiro: Editora Médica e Científica Ltda., 2002.
53. Cvitkovitch DG, Yung-Hua L, Ellen RP. Quorum sensing and biofilm formation in streptococcal infections. *J. Clin. Invest.* 2003; 112: 1626-1632.
54. Ghaemi A, Nazari R, Hamdi K, Ordouzadeh N, Amirmozafari N, Hassani AS. Volatile components of *Camélia sinensis* inhibit growth and biofilm formation of oral *streptococci in vitro*. *J. Biol. Sci.* 2008; 11(10): 1336-1341.
55. Dashper SG, Reynolds EC. Lactic acid excretion by *Streptococcus mutans*. *Microbiol.* 1996; 142: 33-39.

56. Ooshima T, Matsumura M, Hoshino T, Kawabatas T, Soube S, Fujiwara T. Contributions of three glycosyltransferases to sucrose-dependent adherence of *Streptococcus mutans*. J Dent Res. 2001; 80: 1672-1677.
57. Drumond MRS, Castro RD, Almeida RVD, Pereira MSV, Padilha WWN. Estudo comparativo in vitro da atividade antibacteriana de produtos fitoterápicos sobre bactérias cariogênicas. Pesq Bras Odontoped ClinIntegr. 2004; 4(1): 33-38.
58. Leite B, Pascholati SF, Kitajima EW, Ishida ML. Mecanismos de adesão de bactérias e fungos às plantas hospedeiras. Revisão Anual de Patologia de Plantas. 2001; 9: 1-41.
59. Borba AM, Macedo M, Walter LRF. Alternative dentistry with medicinal plants in Chapada dos Guimarães–MatoGrosso, Brazil. South Braz Dent J. 2008; 5(1): 43-49.
60. Palombo E. Traditional medicinal plant extracts and natural products with activity against oral bacteria: potential application in the prevention and treatment of oral diseases. Oxford J. 2009; 1-26.
61. Jardim EG, Pedrini D, Xavier EA, Jardim PS. Eficácia do listerine sobre a placa. RGO. 1998; 46: 70-78.
62. Soejarto DD. Biodiversity prospecting and benefit sharing: perspectives from the field. J Ethnopharmacol. 1996; 51: 1-15.
63. Kuklinski C. Farmacognosia, estudio de las drogas y sustancias medicamentosas de origen natural. Barcelona.Omega; 2000.
64. Yunes RA, Cechinel FV. Breve análise histórica de plantas medicinais: sua importância na atual concepção de fármaco segundo os paradigmas ocidental e oriental. In: Yunes RA, Calixto JB. (Ed.). Plantas medicinais sob a óptica da química medicinal moderna. Chapecó. Argos; 2001.
65. Lorenzi H, Matos FJA. Plantas medicinais do Brasil: nativas exóticas. Instituto Plantarum de Estudos da Flora; 2002.
66. Roberts M. Indigenous Healing Plants, Southern Books, Pretoria, South Africa, 1990.
67. Hutchings A, Scott AH, Lewis G, Cunningham AB. Medicinal Plants: An Inventory, University of Natal Press, Pietermaritzburg, South Africa, 1996.
68. *Erythrina* in Flora do Brasil 2020 em construção. Jardim Botânico do Rio de Janeiro. Disponível em: <<http://reflora.jbrj.gov.br/reflora/floradobrasil/FB105155>>. Acesso em: 30 Mar. 2017
69. Onusic GM, Nogueira RL, Pereira AMS, Viana MB. Effect of acute treatment with a water-alcohol extract of *Erythrina mulungu* on anxiety-related responses in rats. Braz J MedBiol Res. 2002; 35: 473–477.

70. Burkill H. The useful plants of West Tropical Africa. London: Royal Botanic Garden Kew; 1985.
71. Vasconcelos SMM, Lima NM, Sales GTM, Cunha GMA, Aguiar LMV, et al. Anticonvulsant activity of hydroalcoholic extracts from *Erythrina velutina* and *Erythrina mulungu*. J Ethnopharmacol. 2007; 110: 271–274.
72. Vasconcelos SMM, Oliveira GR, Carvalho MM, Rodrigues ACP, Silveira ER, et al. Antinociceptive activities of the hydroalcoholic extracts from *Erythrina velutina* and *Erythrina mulungu* in mice. Biol Pharm Bull. 2003; 26: 946–949.

ANEXO

ANEXO A – Normas do periódico Brazilian Journal of Microbiology



GUIDELINES TO AUTHORS

SCOPE OF THE JOURNAL

Brazilian Journal of Microbiology, published by the Brazilian Society of Microbiology, publishes original research papers and reviews, covering all aspects of Microbiology. The publication fee for this journal is **USD 300** for non-Brazilian citizens, and, **R\$ 840,00** for Brazilian citizens.

The following categories of papers are acceptable for publication in Brazilian Journal of Microbiology:

- **Research paper:** the research paper reports results of original research, which has not been published elsewhere.
- **Short Communication:** a Short Communication is new and significant findings. Submit form is the same way as research paper. They receive the same review, they are not published more rapidly than research paper.
- **Short-review:** Review articles should deal with microbiological subjects of broad interest (ONLY BY INVITATION).
- **Letter to the editor:** Letters to the Editor are intended only for comments on final, typeset articles published in the journal (manuscripts posted online are not accepted) and must cite published references to support the writer's argument.

Your manuscript must be written clearly, in **comprehensible English**.

The text submitted for publication has to be English reviewed before **submission**. **To submit the manuscript, you must attach the issued certificate in supplementary files.**

SECTIONS

Biotechnology and Industrial Microbiology**Bacterial Fermentation**

- biosynthesis and bioconversion of natural products, including antibiotics, xenobiotics, and macromolecules produced by bacteria.
- molecular aspects of bacterial biotechnology

Fungal Fermentation

- biosynthesis and bioconversion of natural products, including antibiotics, xenobiotics, and macromolecules produced by fungi
- molecular aspects of fungal biotechnology

Food Microbiology**Technology**

- applications of microorganisms (bacteria and fungi) for food production

Safety and Quality

- food borne diseases
- food spoilage
- microbial ecology in foods

Clinical Microbiology**Bacteria, Fungi, and Virus**

- Laboratory diagnosis of human infections and the role of the laboratory in both the management of infectious diseases and the elucidation of the epidemiology of infections.
- Microbial resistance and mechanisms of antimicrobial agents.

Environmental Microbiology**Microbial Ecology**

- ecology of natural microbial assemblages, microbial diversity of natural environments such as water, soil, sediments and higher organisms
- microbial interactions
- environmental aspects of public health
- biodegradation
- bioremediation

Bacterial and Fungal Molecular Pathogenesis

- Genetic, biochemical, and structural basis of bacterial and fungal pathogenesis

Bacterial and Fungal Physiology

- Biochemistry, biophysics, metabolism, cell structure, stress response, growth, differentiation, and other related process of bacteria and fungi

Veterinary Microbiology

- control and/or treatment of animals
- animal pathogen diagnostics
- veterinary or zoonotic pathogens

SUBMISSION OF A MANUSCRIPT

Submission of a manuscript to Brazilian Journal of Microbiology is understood to imply that it has not

GUIDELINES TO AUTHORS

previously been published (except in an abstract form) and that it is not being considered for publication elsewhere.

Upon receipt of a manuscript all authors will receive an electronic message acknowledging the receipt.

Responsibility for the accuracy of the manuscript content lies entirely with the authors.

PUBLICATION OF A MANUSCRIPT

Manuscripts are accepted for publication after having been critically reviewed by at least two referees, indicated by the Editors.

The suggestions and recommendations of the reviewers and Editors will be forwarded electronically to the corresponding author, who should return the reviewed manuscript to the Editors within the stipulated date, via online system. Whenever applicable, the corresponding author should explain or comment each modification introduced in the text.

The corresponding author will receive an electronic message whenever the manuscript moves from one status to the next.

Membership in Brazilian Society for Microbiology is not a pre requisite for submission of a manuscript for publication.

Nonmember scientists from Brazil and other countries are invited to submit papers for analysis.

ETHICS

When the study, described in the manuscript, is related to experiments carried out with human beings and/or animals, author(s) must inform, within the text, if the research project has been approved by the Research Ethics Committee of their institution, according to the Declaration of Helsinki (http://www.fcm.unicamp.br/fcm/sites/default/files/declaracao_de_helsinque.pdf). Experimental studies involving animals should follow the guidelines established by the "Guide for the Care and Use of Laboratory Animals" (<http://www.ncbi.nlm.nih.gov/books/NBK54050/>) (Institute of Laboratory Animal Resources, National Academy of Sciences, Washington, D. C. 1996), and the *Princípios Éticos na Experimentação Animal do Colégio Brasileiro de Experimentação Animal (COBEA)* (Ethical Principles for Animal Experimentation of the Brazilian College of Animal Experimentation - http://www.cobea.org.br/conteudo/view?ID_CONTEUDO=65).

PREPARATION OF A MANUSCRIPT

The manuscript should be submitted as one single WORD file. This single file should include: the whole text, figures, tables, etc. Only manuscripts written in English will be considered.

For **research papers**, the WORD file should contain:

- Title (100 characters)
- Running title (40 characters)
- Authors and Affiliations
- Abstract (up to 200 words)
- Three to five key-words
- Introduction
- Materials and Methods
- Results
- Discussion
- Acknowledgements (optional)
- References

For **short communications**, the WORD file should contain:

- Title
- Running title
- Authors and Affiliations
- Abstract (up to 50 words)
- Three to five key-words
- Text not divided in topics
- Acknowledgements (optional)
- References

For **short-review**, the WORD file should contain:

- Title (100 characters)
- Running title (40 characters)
- Authors and Affiliations
- Abstract (up to 200 words)
- Three to five key-words
- Text
- Acknowledgements (optional)
- References

For **Letter to the Editor** the WORD file should contain:

- Title (100 characters)
- Running title (40 characters)
- Authors and Affiliations
- Text (no more than 500 words and must be typed double-spaced)
- References

Author affiliations should be presented in decreasing hierarchical order (e.g. Harvard University, Harvard Business School, Boston, USA) and should be written as established in its own language (e.g. Université Paris-Sorbonne; Harvard University, Universidade de São Paulo).

All manuscripts should be typed double-spaced with 3 cm margins and pages should be numbered sequentially. The lines in each page of the manuscript should be numbered too. The Editors recommend that a manuscript should be critically read by someone fluent in English before submission.

Manuscripts written in poor English will not be accepted.

Research papers and *short-review* consist of 20 pages, including references, tables and figures.

Abbreviations of terms and symbols should follow the recommendations of IUPAC-IUB Commission

(*Commission on Biochemical Nomenclature, Amendments and Corrections*) and the units are to be used according to SI (*International Systems of Units*).

Suggested Reviewers

Authors may submit suggestions of reviewers to evaluate the manuscripts. The following information must be provided: reviewer name, e-mail address, and the home institution.

Use of plant extracts in microbiological experiments

Articles that present studies with plant extracts, or other complex substances, will be accepted only after identification of compounds.

ORGANIZATION

The full **Title** of the article should be as brief as possible, not exceed 100 characters including spaces, should not contain abbreviations, and be truly indicative of the subject of the paper. Authors should suggest a **Running title** that appears in the page header which should not exceed 40 characters, including spaces.

Expressions like "Effects of", "Influence of", "Study on", etc, should be avoided. Care should be exercised in preparing the title since it is used in literature retrieval systems.

The **Abstract** should summarize the basic content of the paper. The abstract should be meaningful without reference to the text. An abstract should not contain references, tables or unusual abbreviations. Abstracts are reprinted by abstracting journals and therefore will be read by persons who do not have access to the entire paper.

The **Introduction** should provide the reader with sufficient information so that the results reported in the paper can be properly evaluated without referring to the literature. However, the introduction should not be an extensive review of the literature. The introduction should also give the rationale for and objectives of the study that is being reported.

The **Materials and Methods** section should provide enough information for other investigators to repeat the experiments.

Repetition of details of procedures which have already been published elsewhere should be avoided. If a published method is modified, such modification(s) must be described in the paper. Sources of reagents, culture media and equipment (company, city, state, country) should be mentioned in the text. Names that are registered trade marks should be so indicated. Subheading often makes this section easier to read and understand.

The **Results** section should, by means of text, tables and/or figures, give the results of the experiments, extensive interpretation of results has to be avoided but do so in the *Discussion* section. Tables and figures should be numbered using Arabic numerals. All tables and figures must be mentioned in the text.

The approximate location of tables and figures in the text should be indicated.

The **Discussion** section should discuss the results in relation to the literature cited.

In-text citations: Indicate references by (consecutive) superscript arabic numerals in the order in which they appear in the text. The numerals are to be used outside periods and commas, inside colons and semi-colons. For further detail and examples you are referred to the *AMA Manual of Style, A Guide for Authors and Editors*, Ninth Edition, ISBN 0-683- 40206-4, copies of which may be ordered from Lippincott Williams & Wilkins (<http://www.lww.com/index.html>).

Data references: This journal encourages you to cite underlying or relevant datasets in your manuscript by citing them in your text and including a data reference in your Reference List. Data references should include the following elements: author name(s), dataset title, data repository, version (where available), year, and global persistent identifier. Add [dataset] immediately before the reference so we can properly identify it as a data reference. This identifier will not appear in your published article. [dataset] 5. Oguro M, Imahiro, S Saito, S Nakashizuka, T. Mortality data for Japanese oak wilt disease and surrounding forest compositions, Mendeley. Data, v1; 2015. <http://dx.doi.org/10.17632/xwj98nb39r.1>

Reference list: Number the references in the list in the order in which they appear in the text.

General rules from the 10th edition

- Items are listed numerically in the order they are cited in the text
- Include up to 6 authors
- For more than six, provide the names of the first three authors and then add et al

Examples:

1. Paivio A, Jansen B, Becker LJ. Comparisons through the mind's eye. *Cognition*. 1975;37(2): 635-647.
2. Yuen AWC. Lamotrigine: a review of antiepileptic efficacy. *Epilepsia*. 1994;35(suppl 5):S33-S36.
3. Glaser R, Bond L, eds. Testing: concepts and research. *Am Psychol*. 1981;36 [special issue].
4. Yasuda N, Takagi S-i, Toriumi A. Spectral shape analysis of infrared absorption of thermally grown silicon dioxide films. *Appl Surf Sci*. 1997;117-118(June (II)):216-220.
5. Assink EHM, Verloop N. Het aanleren van deel-geheel relaties [Teaching part-whole relations]. *Pedagogische Studiën*. 1977;54:130-142 [in Dutch].
6. H1 Collaboration. *Nucl Phys B*. 1997;504:3.
7. Weikert S, Freyer D, Weih D, et al. Rapid Ca²⁺-dependent NO-production from central nervous system cells in culture measured by NO-nitrite/ozone chemoluminescence. *Brain Res*. 1997;748: 1-11.
8. VanDecar JC, Russo RM, James DE, Ambeh WB, Franke M. Aseismic continuation of the Lesser Antilles slab beneath northeastern Venezuela. *J Geophys Res*. 2003;108:2043. doi:10.1029/2001J B000884.

GUIDELINES TO AUTHORS

9. Strunk Jr W, White EB. *The Elements of Style*. 3rd ed. New York: MacMillan; 1979 [chapter 4].
10. *College Bound Seniors*. Princeton, NJ: College Board Publications; 1979.
11. Luria AR. *The Mind of a Mnemonist* [Solotarof L, Trans.]. New York: Avon Books; 1969 [Original work published 1965].
12. Letheridge S, Cannon CR, eds. *Bilingual Education: Teaching English as a Second Language*. New York: Praeger; 1980.
13. Chaddock TE. Gastric emptying of a nutritionally balanced liquid diet. In: Daniel EE, ed. *Proceedings of the Fourth International Symposium on Gastrointestinal Motility*. Vancouver, British Columbia, Canada: Mitchell Press; 1974:83-92.
14. Adams MJ, Briscoe BE, Sinha SK. Interface friction and energy dissipation in soft solid processing applications. In: Dowson D, Taylor CM, Childs THC, Godet M, Dalmas G, eds. *Dissipative Processes in Tribology*. Amsterdam: Elsevier; 1994:223-234. Dowson D, ed. *Tribology Series*; vol. 27.
15. Wilson JG, Fraser FC, eds. *Handbook of Teratology*. Vols 1-4. New York: Plenum Press; 1977-1978.
16. Sluzki CE, Beavin J. Symmetry and complementarity. In: Watzlawick P, Weakland JH, eds. *The Interactional View*. New York: Norton; 1977:71-87. Reprinted from: *Acta Psiquiatr Psicol Am Lat*. 1965;11:321-330.
17. Yu F, Wu X-S. *Phys Rev Lett*. 1992;68:2996. Available from: hep-th/9112009.
18. Douglas F, Ball Th. Tracking and viewing changes on the web. In: *Proc. 1996 USENIX Technical Conference*; 1996.
19. See the references in: Buchdahl HA. *The Concepts of Classical Thermodynamics*. First published by Cambridge University Press; 1966. Also available electronically as *The Concepts of Classical Thermodynamics* [Last updated 1999]. This reference discusses the basic concepts in a very thorough manner. Its literature list is a main entry point into the discipline.
20. Cancer Research UK. *Cancer statistics reports for the UK*; 2003 Accessed 13.03.03.

ACKNOWLEDGMENTS: This section is optional. It acknowledges financial and personal assistance.

TABLES: should be inserted in the text according to which they are cited, and numbered sequentially in Arabic number. The title of a table should be placed in the top of it and should be brief but fully descriptive of the information contained. Headings and subheadings should be concise with columns and rows of data carefully centered below them. Should be of sufficient quality to ensure good reproduction. Please, open the following link to see the requirements to obtain the adequate resolution. (http://www.ncbi.nlm.nih.gov/pmc/about/image_quality_table.html)

FIGURES: should be inserted in the text according to which they are cited, and numbered sequentially in

Arabic number. Data presented in the tables should not be repeated in the figures. The legend of the figures should be placed at their bottom. Should be of sufficient quality to ensure good reproduction. Please, open the following link to see the requirements to obtain the adequate resolution. (http://www.ncbi.nlm.nih.gov/pmc/about/image_quality_table.html)

PHOTOGRAPHS: Should be of sufficient quality to ensure good reproduction. Please, open the following link to see the requirements to obtain the adequate resolution. (http://www.ncbi.nlm.nih.gov/pmc/about/image_quality_table.html)

CONFLICTS OF INTEREST

It is Brazilian Journal of Microbiology policy that everyone involved in the publication process (authors, reviewers, editorial board members, and editorial staff) must be free from conflicts of interest that could adversely influence their judgment, objectivity or loyalty to the article and assignments. The BJM recognizes that any potential conflict of interest raised must be disclosed promptly to Editor. Conflicts of interest in publishing can be defined as conditions in which an individual holds conflicting or competing interests that could bias editorial decisions. Conflicts of interest may be only potential or perceived, or they may be factual. Personal, political, financial, academic, or religious considerations can affect objectivity in numerous ways.

AUTHORS' COPYRIGHT

Upon receipt of the galley proofs for approval, authors of approved manuscripts should fax or email the Author's Copyright Statement to the BJM (55-11-3037-7095, bjm@sbmicrobiologia.org.br). The statement (see text below) must be signed by at least one of the authors (who agrees to inform the other authors, if any).

TRANSFER OF AUTHORS' COPYRIGHT

"The undersigned author(s) state(s) that the article being submitted is original, does not infringe copyright laws or any other third-party property rights, has not been previously published, and is not being considered for publication elsewhere. The author(s) confirm(s) that the final version of the manuscript has been reviewed and approved by all authors. All manuscripts published become the permanent property of the Brazilian Journal of Microbiology and can not be published without authorization in writing from its Editors."

GUIDELINES TO AUTHORS

Article No. _____

Title of the article: " _____
_____ "

Name(s) of the author(s)

Signature(s)

_____	_____
_____	_____
_____	_____

Date: ____/_____/_____